NewzIntel.com

Category: Transport

  • MIL-Evening Report: The Coalition prepares to soften Australia’s 2030 climate target, while reaffirming its commitment to the Paris Agreement

    Source: The Conversation (Au and NZ) – By Tony Wood, Program Director, Energy, Grattan Institute

    The Coalition has been forced to reassert its commitment to the Paris climate agreement after its energy spokesman Ted O’Brien appeared to waver on the pledge on Thursday.

    O’Brien faced off against Climate Change and Energy Minister Chris Bowen at a debate in Canberra, weeks out from a federal election in which energy policy is emerging as a hot-button issue.

    Under the landmark Paris deal, Australia has pledged to cut greenhouse gas emissions by 43% by the end of the decade, compared to 2005 levels. O’Brien on Thursday said the Coalition would review the target if it wins office. He deflected a question on whether a Dutton government would remain a signatory to the Paris Agreement, saying the Coalition would “always act in the national interest”.

    Within hours of the debate, the Coalition was forced to clarify O’Brien’s comments and reaffirm its commitment to Paris. But the Coalition appears intent on winding back the 2030 target if it is elected next month – a move that would weaken our bipartisan commitment to net zero by 2050 and be against the interests of the global climate.

    The 2025 Climate and Energy debate | ABC NEWS.

    Resetting the 2030 target

    The Coalition has long disputed Labor’s claims that the 43% target would be met.

    In June last year, Opposition Leader Peter Dutton claimed the Albanese government has “no hope of achieving the targets and there’s no sense signing up to targets you don’t have any prospect of achieving”.

    In January this year, Dutton said a Coalition government would remain party to Paris, despite United States President Donald Trump’s move to withdraw his nation from the deal.

    On Thursday, O’Brien confirmed a Coalition government would review the 43% target. In doing so, it would consider three factors: Australia’s emissions trajectory, the state of the economy and the Coalition’s suite of policies – including nuclear power and more gas.

    O’Brien went on to say:

    Labor, the Coalition, nobody in this country will be able to achieve the emission target set by Chris Bowen and Anthony Albanese. The difference between Peter Dutton and Anthony Albanese is that Peter Dutton has been honest and upfront about that.

    O’Brien would not rule out withdrawing Australia from the Paris deal, but later released a statement saying the Coalition remained committed to the agreement.

    Will Australia meet the 43% target?

    During the debate, Bowen claimed Australia is “on track” to meet its emissions-reduction goal. He pointed to analysis by his department released late last year showing emissions are projected to be 42.6% below 2005 levels in 2030.

    Australia will have to work hard to meet the target, with our emissions reductions having stalled since 2021. The government’s projection assumes it achieves its target of 82% renewable electricity generation by 2030 – possible but very challenging from about 45% today.

    It also depends on two policies to reduce emissions outside electricity, neither of which have yet demonstrated their progress.

    The first is the safeguard mechanism, which aims to reduce emissions from heavy industry. It began in mid-2023 but its results are not yet clear. Second is the new vehicle efficiency standard, introduced from January this year.

    What if Dutton does walk back Australia’s Paris commitment?

    Even if a Dutton government remained in the Paris Agreement, walking back on the 43% emissions target is problematic, for a number of reasons.

    Most obviously is that the threat of dangerous climate change is real, and growing. The Paris deal aims to keep average global temperatures “well below” 2°C above pre-industrial levels, and ideally, limit warming to no more than 1.5°C.

    But according to official data, Earth’s monthly global average temperature exceeded 1.5°C above pre-industrial levels for 11 months last year. So meeting the Paris commitment is already looking shaky.

    While the Paris Agreement is a legally binding international treaty, there has been much debate as to the real meaning of “legally binding”. Some argue that national commitments to reduce emissions are not legally binding, and can be revised in either direction. While a downward revision is liable to draw criticism, it could be a legally available option under the Paris Agreement. Transgressors don’t get kicked out of the club.

    But any downward revision on the targets is a bad look on the global stage. University of Melbourne climate law expert Jacqueline Peel has argued that any moves by a future Coalition government to water down Australia’s 2030 target, or to submit a 2035 target weaker than our current pledges, would:

    go against the spirit, if not the letter, of the Paris Agreement, and – in some circumstances – could constitute a breach of those obligations.

    Where to now?

    The Albanese government chose not to announce a 2035 target before the election. The Opposition says it won’t set a 2035 target until it’s in government.

    That means voters will be left in the dark on this important issue as they head to the ballot box.

    At the moment, the Coalition appears to be relying on its controversial nuclear power plan to meet the bipartisan goal of net-zero emissions by 2050. But analysts have warned the plan will lead to much more emissions between now and then.

    Meanwhile, there is far more work to be done outside the energy sector – in agriculture, transport, industry and more – to meet Australia’s climate commitments.

    Australia’s cost of living crisis has garnered much attention during the election campaign so far. There has been very little talk about how Australia’s entire economy will get to net-zero.

    That’s a terrible reflection on the state of our politics. Ultimately, unmitigated climate change will be bad for the planet and very bad for Australia.

    Tony Wood may own shares in companies in relevant industries through his superannuation fund.

    – ref. The Coalition prepares to soften Australia’s 2030 climate target, while reaffirming its commitment to the Paris Agreement – https://theconversation.com/the-coalition-prepares-to-soften-australias-2030-climate-target-while-reaffirming-its-commitment-to-the-paris-agreement-249945

    MIL OSI Analysis – EveningReport.nz –

  • MIL-OSI USA: President Trump’s Actions Will Save Nearly $11,000 Per Family of Four Over the Coming Years

    US Senate News:

    Source: The White House
    TO: WHITE HOUSE COMMS STAFFFROM: CEA STAFFSUBJECT: President Trump’s Actions Will Save Nearly $11,000 Per Family of Four Over the Coming Years President Donald J. Trump has taken major steps to reduce the size of the administrative state and reduce the volume of regulations impacting American households and businesses. The administration expects major cost savings from the President’s aggressive deregulatory agenda as firms respond to the improved business environment over the next several years. Upon taking office, President Trump immediately blocked all unfinalized Biden era rules, saving Americans over $180 billion — $2,100 per family of four — and launched a bold, multi-agency effort to roll back existing federal regulations that drive up the cost of living. This effort is projected to yield significant cost savings in the coming months, including the EPA’s rollback of tailpipe emission rules for light-duty and medium-duty vehicles ($667 billion in total savings) and the Department of Transportation’s latest Corporate Average Fuel Economy (CAFE) standards ($88 billion in savings). These two efforts alone yield $755 billion in total savings or over $8,800 per family of four. The combined savings from all of these actions equal just over $935 billion or nearly $11,000 per family of four over the coming years.
    The Trump Administration has implemented an aggressive 10-to-1 deregulatory initiative, which requires that whenever an agency proposes a new rule or guidance document, it must eliminate 10 existing rules or guidance documents. This effort builds on the successful deregulatory initiative introduced in President Trump’s first term, which required the repeal of at least two existing regulations for each new rule, and in practice eliminated 5.5 rules for each new significant rule.
    President Trump has already issued more than a dozen presidential actions mandating a wide range of deregulatory relief, including:
    Emergency measures to reduce regulatory burdens stifling California’s access to water resources.

    MIL OSI USA News –

  • MIL-OSI Security: Mexican National Admits to Role in Drug Trafficking Operation

    Source: Office of United States Attorneys

    MARTINSBURG, WEST VIRGINIA – Jose Alberto Camarena Rocha, age 31, of Mexico, has admitted to his role in a drug trafficking organization that sold cocaine, heroin, and fentanyl in the Eastern Panhandle of West Virginia. 

    Rocha has pled guilty to conspiracy to possess with intent to distribute and to distribute one kilogram or more of heroin and illegal reentry. According to court documents and statements made in court, Rocha, living in California, used his connections with the Sinaloa Drug Cartel in Mexico to supply controlled substances to the drug trafficking operation. Others then would sell cocaine, heroin, and fentanyl in Berkeley and Jefferson Counties.

    Rocha is facing at least 10 years and up to life in federal prison for the drug charge and faces up to two years for the reentry charge.  A federal district court judge will determine any sentence after considering the U.S. Sentencing Guidelines and other statutory factors.

    Assistant U.S. Attorney Lara Omps-Botteicher is prosecuting the case on behalf of the government.

    The Eastern Panhandle Drug Task Force was the lead investigative unit. Other investigative agencies that assisted include the Federal Bureau of Investigation, including the Pittsburgh, San Francisco, San Juan, and Philadelphia Field Offices; United States Marshals Service; Homeland Security Investigations; United States Postal Service; Drug Enforcement Administration, the Louisville and Chicago Divisions; Bureau of Alcohol, Tobacco, Firearms, and Explosives; West Virginia State Police; Martinsburg Police Department; Ranson Police Department; Charles Town Police Department; Berkeley County Sheriff’s Office; Jefferson County Sheriff’s Office; West Virginia Air National Guard; Mineral County Sheriff’s Office; Grant County Sheriff’s Office; Hampshire County Sheriff’s Department; Keyser Police Department; Northwest Regional Drug Task Force, Virginia; Pennsylvania State Police; Franklin County Sheriff’s Office, Pennsylvania; Winchester Police Department, Virginia; Frederick County Sheriff’s Office, Virginia; Virginia State Police; Sunnyvale Police Department, California.

    This case is part of Operation Take Back America, a nationwide initiative that marshals the full resources of the Department of Justice to repel the invasion of illegal immigration, achieve the total elimination of cartels and transnational criminal organizations (TCOs), and protect our communities from the perpetrators of violent crime. Operation Take Back America streamlines efforts and resources from the Department’s Organized Crime Drug Enforcement Task Forces (OCDETFs) and Project Safe Neighborhood (PSN).

    U.S. Magistrate Judge Robert W. Trumble presided.

    Find the related press release here: https://www.justice.gov/usao-ndwv/pr/twenty-five-charged-drug-trafficking-eastern-panhandle

    MIL Security OSI –

  • MIL-OSI: c/side Launches Channel Partner Program as Zero-Day Web Dependency Attacks—and Compliance Pressure—Accelerate

    Source: GlobeNewswire (MIL-OSI)

    • Third-party web scripts are now the #1 source of web-based data breaches
    • Most companies do not even know which scripts are running on their site
    • PCI DSS 4.0.1 mandates new protections starting March 2025—non-compliance means fines, or worse

    SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) — c/side, which specializes in securing vulnerable web dependencies, today launched its first-ever channel partner program. The new program enables managed service providers (MSPs), web development agencies, and security consultants with new revenue opportunities while protecting their clients from rising web dependency attacks and ensuring PCI DSS 4.0.1 compliance.

    Through a unified management dashboard, partners can offer c/side’s differentiated web security solutions to their clients with simplified onboarding and security monitoring. Early partners will receive priority access to technical support, co-marketing resources, and exclusive onboarding benefits through June 2025.

    Web dependencies loading in website visitors’ browsers (such as first- and third-party web scripts used for payment processing, analytics, and chatbots) are a major security risk to organizations large and small—as headlines continue to show. The most commonly deployed dependencies change weekly, often without a business knowing. When compromised, they can rewrite webpages, change crypto wallet IDs, redirect users to malicious sites, capture keystrokes, and more. Attack consequences range from significant financial damage to compliance issues to potential lawsuits.

    “Our channel partners are on the front lines helping clients across industries secure their websites and their customer data against increasingly sophisticated threats,” said Mike Kutlu, GTM Operations at c/side. “Our new program provides our partners with the tools, resources, and flexible business models they need to protect their clients from the quickly-evolving risks posed by compromised web scripts and other dependencies. With our unified dashboard approach, partners can manage all their client projects efficiently while offering a revenue-generating solution that makes their clients’ websites not just a lot more secure, but also run up to 30% faster.”

    With the PCI DSS 4.0.1 compliance deadline of March 31, 2025, organizations with websites that handle credit card data must implement tamper-detection mechanisms to mitigate increasingly sophisticated browser-side attacks. c/side’s partner program launches at an especially critical time, as businesses seek solutions that can detect unauthorized changes to HTTP headers, scripts, and other dependencies.

    Recent attacks continue to underscore the urgency: a staggering $1.5 billion was stolen in a malicious JavaScript attack on Bybit, while more than 150,000 websites were compromised by a malicious full-page hijack injection.

    c/side’s partners benefit from:

    • Uniquely thorough web security monitoring: Real-time, flow-through monitoring of third-party scripts across entire websites (not just payment portals) with no sampling and 100% coverage.
    • Seamless client management: A single dashboard to manage all client projects without the need for separate accounts or complex onboarding processes.
    • Flexible billing options: Partners can choose consolidated or split billing per customer, tailored to their preferred client relationship model.
    • PCI DSS 4.0.1 compliance support: Tools that help clients meet the strict requirements in sections 6.4.3 and 11.6.1 of the March 2025 enforcement mandate.
    • Advanced detection capabilities: Autonomous detection powered by AI that processes more than 1 million scripts daily and monitors more than 70 attributes to identify potential threats.

    Unlike other solutions that rely on sampling or basic threat feeds, c/side employs historical context and artificial intelligence to review both the payload and behavior of scripts, making it the most advanced detection system in the industry. The platform is compatible with popular e-commerce platforms and front-end technologies including Shopify, Magento, WooCommerce, and Next.js, as well as custom-built and traditional website architectures.

    “With c/side’s partner program, we’re empowering the channel to address a critical security gap that traditional security tools simply cannot handle,” said Simon Wijckmans, CEO and founder, c/side. “Our partners can now provide clients with protection against zero-day attacks while differentiating their services in an increasingly competitive market.”

    “c/side gave us the ability to monitor all of our clients’ websites with zero friction,” said Ben Alexander, Director of HomeMade Digital, a technology partner that helps modernize and secure websites. “The platform has been a game-changer for managing compliance and real-time risk.”

    MSPs, web development agencies, and security consultants, interested in joining c/side’s partner program can visit cside.dev/partners or contact the company at mike@cside.dev

    About c/side

    c/side is a venture-backed cybersecurity company specializing in browser-side threat detection and protection. The company’s platform provides complete visibility and control over vulnerable first- and third-party scripts running on websites, protecting sensitive visitor data while ensuring optimal website performance. c/side’s innovative technology enables customers to secure their web supply chain against sophisticated attacks and streamlines compliance with regulations such as PCI DSS 4.0.1.

    Contact
    Kyle Peterson
    kyle@clementpeterson.com

    The MIL Network –

  • MIL-OSI United Kingdom: Woolwell to the George update – April 2025

    Source: City of Plymouth

    View from Woolwell Roundabout looking north along Tavistock Road

    Work on the first phase of the Woolwell to The George transport improvement scheme is progressing well and remains on schedule.

    All major utility diversions have now been completed and work on the new junction at Woolwell Crescent continues, with preparations now being made to build the new toucan crossing on Tavistock Road. This will involve reducing a short section of the outbound side of Tavistock Road to one lane until the summer.

    The lane closure, which will protect the workforce as we construct the new crossing and drainage and then work on the central reservation, will be in place from Monday 28 April, with traffic management being put out overnight on Sunday 27 April.

    It was originally programmed for February but postponed to March and now later this month, so we could make some minor scheme design changes to avoid diverting utility services under the footpath.

    We have also made a start on the new retaining wall on the east side of Tavistock Road (alongside Tesco). The wall allows us to widen and create the space to build the new two-way segregated cycle track.

    Plans to complete works on Woolwell Road, which include installing the permanent toucan crossing signals and new street lighting, are also being finalised. They are currently programmed for June and, to avoid significant impacts on traffic flow, will be overnight. Final dates will be confirmed closer to the time.

    Preparations for phase two, which involves widening Tavistock Road between Woolwell Roundabout and the George Park and Ride, as well as the replacement of Woolwell Roundabout with a new signalised junction, are also under way and works are planned to start on site later this year.

    As part of this we have been carrying out targeted investigations, with specialist support, to decide whether it might be possible to retain some of the trees currently identified for removal. This work is part of our ongoing efforts to reduce the impact of the scheme as much as possible and find alternative solutions where we can.

    The Woolwell to The George scheme has been in the pipeline for many years. It will tackle one of Plymouth’s worst traffic bottlenecks and is a vital part of our programme to provide better links to and from the north of Plymouth as it grows.

    In the coming years around 4,400 new homes are planned in the north of the city – including 2,000 new homes at the Woolwell Urban Extension. This and other developments, such as the new district shopping centre in Derriford, will see an increased amount of traffic along this route.

    The whole scheme will cost £45 million, which includes £24.9 million of UK Government funding to support delivery of these vital improvements.

    More information, including traffic management plans and FAQs, can be found on our Woolwell to The George pages.

    For regular updates and advance notifications of road layout changes email Balfour Beatty at [email protected].

    MIL OSI United Kingdom –

  • MIL-OSI: Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 09 04 2025] – (CGWL)

    Source: GlobeNewswire (MIL-OSI)

    FORM 8.3

    PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
    A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
    Rule 8.3 of the Takeover Code (the “Code”)

    1.        KEY INFORMATION

    (a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)
    (b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
            The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    		 N/A
    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
            Use a separate form for each offeror/offeree    		 ADVANCED MEDICAL SOLUTIONS GROUP PLC
    (d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
    (e)   Date position held/dealing undertaken:
            For an opening position disclosure, state the latest practicable date prior to the disclosure    		 09 APRIL 2025
    (f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
            If it is a cash offer or possible cash offer, state “N/A”    		 N/A

    2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

    If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

    (a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

    Class of relevant security: 5p ORDINARY
      Interests Short positions
    Number % Number %
    (1)   Relevant securities owned and/or controlled: 11,862,906 5.4410    
    (2)   Cash-settled derivatives:        
    (3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
    TOTAL: 11,862,906 5.4410    

    All interests and all short positions should be disclosed.

    Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

    (b)      Rights to subscribe for new securities (including directors’ and other employee options)

    Class of relevant security in relation to which subscription right exists:  
    Details, including nature of the rights concerned and relevant percentages:  

    3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

    Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

    The currency of all prices and other monetary amounts should be stated.

    (a)        Purchases and sales

    Class of relevant security Purchase/sale Number of securities Price per unit
    5p ORDINARY SALE 3,240 184.6p
    5p ORDINARY SALE 21,590 198.4p
    5p ORDINARY PURCHASE 3,240 185.5453p

    (b)        Cash-settled derivative transactions

    Class of relevant security Product description
    e.g. CFD    		 Nature of dealing
    e.g. opening/closing a long/short position, increasing/reducing a long/short position    		 Number of reference securities Price per unit
    NONE        

    (c)        Stock-settled derivative transactions (including options)

    (i)        Writing, selling, purchasing or varying

    Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
    e.g. American, European etc.    		 Expiry date Option money paid/ received per unit
    NONE              

    (ii)        Exercise

    Class of relevant security Product description
    e.g. call option    		 Exercising/ exercised against Number of securities Exercise price per unit

    (d)        Other dealings (including subscribing for new securities)

    Class of relevant security Nature of dealing
    e.g. subscription, conversion    		 Details Price per unit (if applicable)
    NONE      

    4.        OTHER INFORMATION

    (a)        Indemnity and other dealing arrangements

    Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
    Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

    NONE

    (b)        Agreements, arrangements or understandings relating to options or derivatives

    Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
    (i)   the voting rights of any relevant securities under any option; or
    (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
    If there are no such agreements, arrangements or understandings, state “none”

    NONE

    (c)        Attachments

    Is a Supplemental Form 8 (Open Positions) attached? NO
    Date of disclosure: 10 APRIL 2025
    Contact name: MARK ELLIOTT
    Telephone number: 01253 376539

    Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

    The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

    The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

    The MIL Network –

  • MIL-OSI: Kaltura and Synthesia Announce Partnership to Deliver the Next Frontier in AI-Powered Video Creation and Distribution

    Source: GlobeNewswire (MIL-OSI)

    New York, April 10, 2025 (GLOBE NEWSWIRE) —

    Kaltura (Nasdaq: KLTR), the AI Video Experience Cloud, today announced a new partnership with Synthesia, a developer of hyper-realistic AI avatars for enterprises. This partnership will enable organizations using Kaltura’s video platform to distribute avatar-based, AI-generated video content at scale, measurably enhancing viewer engagement. With early testing already underway, Kaltura users are employing avatars in a wide variety of use cases across industries including healthcare, pharmaceuticals, technology, telecoms, higher education, and more.   

    As digital paradigms shift, traditional text-based learning struggles to captivate modern audiences, falling short in learning outcome and knowledge retention. By merging Synthesia’s pioneering AI avatars with Kaltura’s immersive AI video capabilities, organizations can now revolutionize learning with hyper-personalized, interactive content that captivates, inspires, and drives deeper knowledge retention. 

    Organizations already leveraging Kaltura’s video platform will be able to integrate AI-generated content and avatars into their workflows, unlocking new possibilities for: 

    • Enterprise Training & Onboarding: AI-generated training modules for employee training, compliance videos, and internal communications. 
    • Higher Education & E-Learning: Automated lecture content, multilingual courses, and AI-driven educational videos for universities and edtech companies.  
    • Marketing & Customer Engagement: AI-powered product demos, hyper-personalized marketing campaigns, and customer onboarding content. 
    • Healthcare & Financial Services: Automated regulatory training and client education videos tailored for compliance-driven industries. 

    Beyond enhancing engagement, the collaboration also reimagines video production, making it more accessible and cost-effective. AI-powered video creation eliminates the need for expensive studio shoots and extensive editing, allowing organizations to generate professional-quality content quickly and efficiently.  

    “At Kaltura, we are redefining the future of video by seamlessly merging personalization with immersive technology. Avatars represent the next evolution in hyper-personalization, transforming static content into dynamic, interactive experiences. Our collaboration with Synthesia is a bold step forward, setting new industry benchmarks for AI video innovation,” said Navi Azaria, Chief Product and Engineering Officer at Kaltura. 

    “Through our partnership with Kaltura, we will be able to bring our avatars to a broader audience and unlock new market opportunities,” said Brian Jambor, Head of Partnerships at Synthesia. “We’re looking forward to exploring new use cases, from enhancing enterprise training programs to tailoring education and employee onboarding.” 

    Learn more about Kaltura AI-infused video solutions, here.   

      

    About Kaltura 

    Kaltura’s mission is to create and power AI-infused hyper-personalized video experiences that boost customer and employee engagement and success. Kaltura’s AI Video Experience Cloud includes a platform for enterprise and TV content management and a wide array of Gen AI-infused video-first products, including Video Portals, LMS and CMS Video Extensions, Virtual Events and Webinars, Virtual Classrooms, and TV Streaming Applications. Kaltura engages millions of end-users at home, at work, and at school, boosting both customer and employee experiences, including marketing, sales, and customer success; teaching, learning, training and certification; communication and collaboration; and entertainment and monetization. For more information, visit  www.corp.kaltura.com 

    About Synthesia 

    Synthesia is the world’s leading enterprise AI video platform. Over 1 million users across 65,000 businesses, including more than 60% of the Fortune 100, use it to communicate efficiently and share knowledge at scale using AI avatars. Founded in 2017, Synthesia is headquartered in London and makes video creation, collaboration and sharing easy for everyone. To learn more, visit www.synthesia.io  

    The MIL Network –

  • MIL-OSI: Willis appoints Dom Spinelli Head of Transactional Insurance Claims in North America

    Source: GlobeNewswire (MIL-OSI)

    NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) — Willis, a WTW business (Nasdaq: WTW), today announced the appointment of Dom Spinelli as Head of Transactional Insurance Claims for North America. In this role, he will lead the claims function within Willis’ Alternative Asset Insurance Solutions (AAIS) industry vertical division, overseeing the entire lifecycle of transactional insurance claims, including representations and warranties, tax, and contingent matters.

    Spinelli brings 15 years of experience in insurance and litigation to the role, enhancing Willis’ transactional claims capabilities while also supporting the expansion of services for clients navigating complex deal-related risks. Most recently, he served as Head of Contingent & Litigation Risk for North America at VALE Insurance Partners, after leading the contingent legal risk insurance team at Liberty Global Transaction Solutions and working as a representations and warranties insurance underwriter. Earlier in his career, Spinelli was a litigator, managing a wide range of commercial and insurance coverage disputes across the U.S.

    In addition to his litigation background, Spinelli has represented insurers in hundreds of complex claims across nearly every line of insurance. He is the only claims professional with senior-level experience on both the underwriting and claims sides, offering clients a rare and valuable perspective on maximizing outcomes. His expertise will not only enhance Willis’s ability to support clients throughout the claims process, but also provide critical value at the outset of a transaction, helping structure policies appropriately from the start.

    Based in Boston, Spinelli will report to Simone Bonnet, Head of Transactional Insurance Solutions, North America at Willis.

    “Dom’s extensive experience—spanning litigation, underwriting, and claims—gives him a unique ability to guide clients through the most challenging aspects of transactional insurance,” commented Bonnet. “His diverse expertise strengthens our ability to provide innovative and effective solutions. We are excited to have him join the team and look forward to the valuable contributions he will make.”

    Spinelli holds a BA from Providence College and a JD from the University of Connecticut School of Law. He is admitted to practice law in Massachusetts, Connecticut, Illinois, and the Southern and Eastern District Courts of New York.

    About WTW

    At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk, and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce, and maximize performance.

    Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you.
    Learn more at wtwco.com.

    Media Contact

    Douglas Menelly
    Douglas.Menelly@wtwco.com | +1 (516) 972-0380

    Arnelle Sullivan
    Arnelle.Sullivan@wtwco.com | +1 (718) 208-0474

    The MIL Network –

  • MIL-OSI: American Rebel CEO Andy Ross Appears on Miami TV WSFL – Home of the Florida Panthers and is Featured in the New York Post for his Meetings at Mar-A-Lago as the Brand Continues to Expand its Footprint in Florida 

    Source: GlobeNewswire (MIL-OSI)

    Miami Television Appearance and Investor Meetings at Mar-a-Lago Signal Big Moves for the Nation’s Fast-Growing Beer Brand – American Rebel Light Beer

    Nashville, TN, April 10, 2025 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), creator of American Rebel Beer (americanrebelbeer.com) and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel (americanrebel.com), is excited to share its CEO Andy Ross’ TV interview on Miami’s WSFL – Home of the Florida Panthers and the New York Post’s coverage of Andy’s meetings with investors and members at Mar-a-Lago, dubbed “The Winter White House.”

    “We had very productive meetings at Mar-a-Lago with like-minded patriots and potential investors,” said Andy Ross, CEO of American Rebel. “Florida is near the top of our list of states we’re planning to expand. We believe Florida will love America’s Patriotic, God Fearing, Constitution Loving, National Anthem Singing, Stand Your Ground Beer. It’s an honor and a blessing to be a guest at Mar-a-Lago and to be launching our beer at what I believe will be a historic time for our country.”

    WSFL interview can be found here:
    From Music to Malts: Andy Ross Brings American Rebel Beer to Florida
    https://www.wsfltv.com/inside-south-florida/from-music-to-malts-andy-ross-brings-american-rebel-beer-to-florida

    New York Post article can be found here:
    https://pagesix.com/2025/04/08/society/celebratory-mood-at-mar-a-lago-despite-market-drop-after-trumps-liberation-day-tariffs-felt-like-a-rally/

    About American Rebel Light Beer

    Produced in partnership with AlcSource, American Rebel Light Beer (americanrebelbeer.com) is a premium domestic light lager celebrated for its exceptional quality and patriotic values. It stands out as America’s Patriotic, God-Fearing, Constitution-Loving, National Anthem-Singing, Stand Your Ground Beer.

    American Rebel Light is a Premium Domestic Light Lager Beer – All Natural, Crisp, Clean and Bold Taste with a Lighter Feel. With approximately 100 calories, 3.2 carbohydrates, and 4.3% alcoholic content per 12 oz serving, American Rebel Light Beer delivers a lighter option for those who love great beer but prefer a more balanced lifestyle. It’s all natural with no added supplements and importantly does not use corn, rice, or other sweeteners typically found in mass produced beers.

    About American Rebel Holdings, Inc.

    American Rebel Holdings, Inc. (NASDAQ: AREB) has operated primarily as a designer, manufacturer and marketer of branded safes and personal security and self-defense products and has recently transitioned into the beverage industry through the introduction of American Rebel Light Beer. The Company also designs and produces branded apparel and accessories. To learn more, visit www.americanrebel.com and www.americanrebelbeer.com. For investor information, visit www.americanrebelbeer.com/investor-relations.

    American Rebel Holdings, Inc.
    info@americanrebel.com

    American Rebel Beverages, LLC
    Todd Porter, President
    tporter@americanrebelbeer.com

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. American Rebel Holdings, Inc., (NASDAQ: AREB; AREBW) (the “Company,” “American Rebel,” “we,” “our” or “us”) desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “forecasts” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements primarily on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. Important factors that could cause actual results to differ from those in the forward-looking statements include benefits of marketing outreach efforts, actual placement timing and availability of American Rebel Beer, success and availability of the promotional activities, our ability to effectively execute our business plan, and the Risk Factors contained within our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2024. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required by law.

    Company Contact:
    tporter@americanrebelbeer.com
    ir@americanrebel.com

    Media Contact:
    Matt Sheldon
    Matt@PrecisionPR.co

    Attachments

    The MIL Network –

  • MIL-OSI: Cerence AI Honored with HARMAN’s Best Technology Award

    Source: GlobeNewswire (MIL-OSI)

    BURLINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced that it has been awarded the Best Technology Award by HARMAN during its Supplier Awards event held in Budapest. This recognition underscores Cerence AI’s commitment to delivering cutting-edge AI solutions that enhance the in-car experience.

    The Supplier Awards event celebrates HARMAN’s exceptional suppliers who have significantly contributed to HARMAN’s resilience, collaboration, and innovation across its global supply chain. Cerence AI was honored in the Best Technology Award category in recognition of the companies’ long-term, successful collaboration on innovations shaping the future of automotive technology.

    Most recently, at CES 2025, HARMAN introduced its “Luna” avatar powered by Ready Engage, HARMAN’s new emotionally intelligent AI system designed to transform in-car experiences. This system features pre-integration with Cerence AI’s voice assistant, offering personalized AI-powered interactions that anticipate needs and respond naturally through voice and visuals. In addition, the companies integrated Cerence AI’s CaLLM™ Edge SLM, powered by Microsoft, into HARMAN’s Ready Upgrade, making it easier for third-party app developers to create in-car applications that bring consumers’ preferred, personalized content into the vehicle while ensuring that personal data remains secure.

    “We are honored to receive the Best Technology Award from HARMAN, a testament to our ongoing collaboration and shared vision for the future of in-car experiences,” said Christian Mentz, Chief Revenue Officer, Cerence AI. “This recognition reflects our dedication to pushing the boundaries of AI to create intuitive and intelligent interactions between drivers and their vehicles.”

    “The HARMAN Supplier Awards was more than a celebration—it was a powerful reminder of what we can achieve when we move as one with our partners,” said Dave Parker, Senior Vice President, Procurement and Best Cost Analytics, HARMAN. “These recognitions reflect the shared pursuit of excellence that drives our industry forward and we are proud to recognize Cerence AI for its innovative technology and continued collaboration.”

    To learn more about Cerence AI, visit www.cerence.ai, and follow the company on LinkedIn.

    About Cerence Inc.
    Cerence Inc. (NASDAQ: CRNC) is a global industry leader in creating intuitive, seamless, AI-powered experiences across automotive and transportation. Leveraging decades of innovation and expertise in voice, generative AI, and large language models, Cerence powers integrated experiences that create safer, more connected, and more enjoyable journeys for drivers and passengers alike. With more than 500 million cars shipped with Cerence technology, the company partners with leading automakers, transportation OEMs, and technology companies to advance the next generation of user experiences. Cerence is headquartered in Burlington, Massachusetts, with operations globally and a worldwide team dedicated to pushing the boundaries of AI innovation. For more information, visit www.cerence.ai.

    Contact Information

    Kate Hickman | Tel: 339-215-4583 | Email: kate.hickman@cerence.com

    The MIL Network –

  • MIL-OSI: TransUnion’s OneTru™ Accelerates Product Innovation, Delivering Exceptional Results

    Source: GlobeNewswire (MIL-OSI)

    CHICAGO, April 10, 2025 (GLOBE NEWSWIRE) — One year ago, TransUnion (NYSE: TRU) introduced its transformative OneTru™ solution enablement platform for managing, governing, analyzing and delivering data, identity and insights. Today, OneTru delivers on its promises, accelerating and expanding the pace and breadth of the company’s innovation.

    Over the course of 2024 and early 2025, OneTru capabilities have powered several of TransUnion’s B2B product lines:

    • TransUnion’s alternative lending bureau is now enabled by OneTru, leading to new and enhanced solutions, including TruVision credit risk products that enrich lenders’ existing underwriting scores.
    • Identity capabilities for the TruAudience line of products have been unified on OneTru, enabling more persistent views of identity whether planning, executing or measuring marketing efforts.
    • TruValidate fraud solutions powered by the platform have improved fraud capture rates and decreased manual reviews and false positives.

    OneTru is currently operational in the U.S. and India, and TransUnion plans to expand the platform soon to Canada, the Philippines and the U.K.

    “We continue to build on OneTru’s success by expanding its underlying capabilities, including identity attributes, enhanced matching, decisioning and AI tools to improve efficiency,” said Chris Cartwright, President and CEO, TransUnion. “Our progress enhances the performance of our seven global product lines, delivering better overall quality and accelerating time-to-insights for our customers.”

    Products Powered by OneTru Deliver Better Customer Results

    In just one year, products powered by the OneTru platform have delivered better results for customers:

    • A major financial institution increased their fraud capture rates by 162% using TruValidate fraud solutions.
    • A FinTech leveraged the TruIQ Analytics Studio to build lending models in near real-time, reducing development time from 10 hours to less than one hour.
    • A U.S. credit card issuer cut its offer timeline from 45 to 21 days using TruIQ Data Enrichment.
    • A leading retailer enhanced its marketing data using TruAudience Identity Enrichment to capture insights from over 100 million daily interactions and maintain a fresh view of over 90 million active customers.

    “Many customer benefits from OneTru stem from our Customer Zero approach, where we internally test new and exciting capabilities before releasing them through our product lines,” said Venkat Achanta, Chief Technology, Data & Analytics Officer at TransUnion. “For instance, our AI capabilities are expanding to enable autonomous decision-making, adaptive learning and proactive execution. We expect that these advancements will support use cases such as audience segmentation, predictive scoring and identity resolution, leading to greater innovation for both the company and our customers.”

    To secure access to an upcoming TransUnion roundtable discussion with Forrester about the future uses of AI and other technology trends, please click here. More information about TransUnion’s solution lines can be found here.

    About TransUnion (NYSE: TRU)

    TransUnion is a global information and insights company with over 13,000 associates operating in more than 30 countries. We make trust possible by ensuring each person is reliably represented in the marketplace. We do this with a Tru™ picture of each person: an actionable view of consumers, stewarded with care. Through our acquisitions and technology investments we have developed innovative solutions that extend beyond our strong foundation in core credit into areas such as marketing, fraud, risk and advanced analytics. As a result, consumers and businesses can transact with confidence and achieve great things. We call this Information for Good® — and it leads to economic opportunity, great experiences and personal empowerment for millions of people around the world.

    http://www.transunion.com/business

    Contact Dave Blumberg
    TransUnion
    Telephone 312-972-6646
    E-mail david.blumberg@transunion.com

    The MIL Network –

  • MIL-OSI: Byrna Technologies Fiscal First Quarter 2025 Results

    Source: GlobeNewswire (MIL-OSI)

    ANDOVER, Mass., April 10, 2025 (GLOBE NEWSWIRE) — Byrna Technologies Inc. (“Byrna” or the “Company”) (Nasdaq: BYRN), a personal defense technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions, today reported select financial results for its fiscal first quarter (“Q1 2025”) ended February 28, 2025.

    Fiscal First Quarter 2025 and Recent Operational Highlights

    • Launched Byrna’s first store-within-a-store concept at Sportsman’s Warehouse flagship location in Saratoga Springs, Utah, with 12 additional locations expected to open by early May.
    • Opened three company-owned retail stores in high-foot-traffic areas in the Greater Nashville Area, Scottsdale, Arizona, and Salem, New Hampshire, generating between $1,000 and $1,700 in daily sales per store in their first full month of operation. A fourth store in Fort Wayne, Indiana is opening today.
    • Increased launcher production capacity by 33% to 24,000 launchers per month and began producing payload ammo rounds at its new Fort Wayne ammo facility, capable of producing 8 million rounds per year.
    • Strengthened domestic sourcing, achieving 92% U.S.-made components for Byrna’s flagship model, the Byrna SD, as part of Byrna’s ongoing ‘Made in America’ initiative.
    • Partnered with celebrity influencers Charlie Kirk, Megyn Kelly, Lara Trump, and Donald Trump Jr. to amplify brand awareness and promote the normalization of less-lethal solutions, while continuing to optimize marketing spend for maximum impact.

    Fiscal First Quarter 2025 Financial Results
    Results compare Q1 2025 to the 2024 fiscal first quarter ended February 29, 2024 unless otherwise indicated.

    Net revenue for Q1 2025 grew 57% year-over-year to $26.2 million from $16.7 million in the fiscal first quarter of 2024 (“Q1 2024”). The strong year-over-year growth was primarily attributable to continuing sales momentum, channel expansion, and broader brand adoption.

    Gross profit for Q1 2025 increased to $15.9 million (61% of net revenue) from $9.6 million (58% of net revenue) in Q1 2024. The increase in gross profit was driven by a reduction in component costs driven by a mid-2024 initiative focused on “design for manufacturability” and the economies of scale resulting from increased production volumes.

    Operating expenses for Q1 2025 were $14.2 million, compared to $9.8 million for Q1 2024. The increase was primarily due to higher variable selling expenses, payroll costs, and increased discretionary marketing spend.

    Net income for Q1 2025 was $1.7 million, a significant improvement from $17,000 for Q1 2024. This increase was driven by an overall increase in product sales.

    Adjusted EBITDA1, a non-GAAP metric reconciled below, for Q1 2025 totaled $2.8 million, compared to $1.2 million in Q1 2024.

    Cash, cash equivalents and marketable securities at February 28, 2025 totaled $19.3 million compared to $25.7 million at November 30, 2024. The decrease reflects planned increases in inventory ahead of the Compact Launcher release and normal seasonal working capital movements. Inventory at February 28, 2025 totaled $23.2 million compared to $20.0 million at November 30, 2024. The Company has no current or long-term debt.

    Management Commentary
    Byrna CEO Bryan Ganz stated: “We delivered a strong start to the fiscal year with 57% revenue growth and our second-highest quarter ever, only 6% below our record $28 million Q4, despite Q1 traditionally being our slowest seasonal period. The strong results reflect continuing sales momentum, increasing adoption of less-lethal self-defense options, and rising brand visibility. As expected, January sales softened due to post-holiday consumer fatigue and waning consumer confidence; however, we saw daily sales improve month-over-month in both February and March. Looking ahead, we believe our performance will continue to be supported by Byrna’s expanding retail footprint, growing Amazon presence, and sustained awareness-building efforts – all of which lay the groundwork for the upcoming Compact Launcher release.

    “We launched our first store-within-a-store at Sportsman’s flagship store in Saratoga Springs, Utah in March, and the partnership is off to a strong start. Byrna products are expected to be available in 12 additional store-within-a-store locations by early May as part of our 13-store pilot program. Each location will be supported by a Byrna representative during the rollout period to help ensure the strongest possible launch. Sportsman’s has demonstrated a strong commitment to the partnership, and we are jointly funding the buildout, with Byrna covering half of the roughly $15,000 cost per installation. Depending on store layout, these store-within-a-store locations will either include a Byrna-branded firing range – converted from a former archery bay – or a self-contained shooting lane with dedicated display cases and shelf space. Separately, Sportsman’s plans to add Byrna point-of-sale displays at an additional 41 locations, which will also include a Byrna shooting experience.

    “Assuming that these stores perform similarly to Byrna’s retail stores, Sportsman’s intends to continue opening the Byrna store-within-a-store installations in additional stores. Based on the early performance of the initial stores, we could expand to approximately 30 store-within-a-store locations by the end of August, with a goal of reaching 50 by year-end and potentially adding another 50 in 2026.

    “At the same time, we opened three company-owned stores in Q1. While our current emphasis is on capital-efficient retail expansion through partnerships like Sportsman’s, we remain excited about the long-term potential of Byrna-branded stores, particularly in regions not served by our retail partners. Additionally, these stores act as flagship stores for Byrna, where we can run training programs, host celebrities, and bring in local groups. Early results for the new stores have exceeded expectations, with daily sales averaging between $1,000 and $1,700 per store. These locations have proven especially effective at reaching first-time Byrna customers, and we’re seeing strong walk-in traffic and local engagement. As we evaluate our broader retail strategy, these stores continue to provide valuable insights into consumer behavior and brand building in high-foot-traffic areas.

    “On the operations front, we increased monthly launcher production capacity to 24,000 units across four active production lines. In the first quarter, we built inventory across our SD and LE platforms in preparation for the launch of the Compact Launcher. While the ultimate launcher mix remains to be seen, our Fort Wayne factory has the flexibility to shift production between CL, SD, and LE models based on real-time demand.

    “In March, we also began producing payload rounds at our new ammunition manufacturing facility in Fort Wayne, Indiana, which has the capacity to produce up to 8 million rounds annually. Several machines are already operational, with additional machines coming online over the next few months to support future volume growth. We also have four additional dosing and welding machines on order as we expect to see significant increases in ammo demand with the release of the Compact Launcher, particularly as the CL uses a .61 caliber round which will only be available from Byrna for the foreseeable future.

    “As part of our commitment to domestic manufacturing, we’ve made significant progress with our ‘Made in America’ initiative. Today, 92% of the components used in the manufacture of our flagship SD launcher are sourced from U.S. suppliers, which is up from just 34% a few months ago. We remain on track to exceed 90% domestic sourcing for all products by the end of 2025, a milestone that enhances our supply chain reliability, reduces tariff risk, and supports our brand story.

    “We continued to refine our roster of celebrity and influencer partners, recently adding personalities such as Megyn Kelly, Charlie Kirk, Lara Trump, and Donald Trump Jr. to our existing lineup. These partnerships support our strategy to normalize the category and reach new audiences across demographic segments.

    “In financial matters, we expect our effective tax rate to increase to approximately 23% in 2025 as we transition into full taxpayer status. Our balance sheet remains strong, and while we expect some working capital investment in Q2 as inventory builds ahead of the CL launch, we will very quickly start turning the inventory into cash once the launcher is released. Accordingly, we anticipate continued cash generation in the second half of the year.

    “With momentum across our channels, scalable partnerships in place, and a highly anticipated new product on the horizon, we remain confident in our ability to continue to execute through 2025 and beyond.”

    Conference Call
    The Company’s management will host a conference call today, April 10, 2025, at 9:00 a.m. Eastern time (6:00 a.m. Pacific time) to discuss these results, followed by a question-and-answer period.

    Toll-Free Dial-In: 877-709-8150
    International Dial-In: +1 201-689-8354
    Confirmation: 13752594

    Please call the conference telephone number 5-10 minutes prior to the start time of the conference call. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 949-574-3860.

    The conference call will be broadcast live and available for replay here and via the Investor Relations section of Byrna’s website.

    About Byrna Technologies Inc.
    Byrna is a technology company specializing in the development, manufacture, and sale of innovative less-lethal personal security solutions. For more information on the Company, please visit the corporate website here or the Company’s investor relations site here. The Company is the manufacturer of the Byrna® SD personal security device, a state-of-the-art handheld CO2 powered launcher designed to provide a less-lethal alternative to a firearm for the consumer, private security, and law enforcement markets. To purchase Byrna products, visit the Company’s e-commerce store.

    Forward-Looking Statements
    This news release contains “forward-looking statements” within the meaning of the securities laws. All statements contained in this news release, other than statements of current and historical fact, are forward-looking. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “expects,” “intends,” “anticipates,” and “believes” and statements that certain actions, events or results “may,” “could,” “would,” “should,” “might,” “occur,” or “be achieved,” or “will be taken.” Forward-looking statements include descriptions of currently occurring matters which may continue in the future. Forward-looking statements in this news release include but are not limited to our statements related to our expected sales during 2025, our ability to scale production lines, Byrna’s ability to remain self-sustaining, profitable and cash flow positive, Byrna’s ability to open new retail locations and realize revenue growth from them, the expected scale, timing and benefits of Byrna’s store-within-a-store partnership with Sportsman’s Warehouse, the benefits and continued success of Byrna’s celebrity endorser strategy, Byrna’s ability to re-shore production and cease purchasing parts from China on the anticipated timeline, the expected benefits of re-shoring production, the anticipated growth and potential size of the U.S. less-lethal market, and Byrna’s positioning for sustained growth in 2025 and 2026. Forward-looking statements are not, and cannot be, a guarantee of future results or events. Forward-looking statements are based on, among other things, opinions, assumptions, estimates, and analyses that, while considered reasonable by the Company at the date the forward-looking information is provided, inherently are subject to significant risks, uncertainties, contingencies, and other factors that may cause actual results and events to be materially different from those expressed or implied.

    Any number of risk factors could affect our actual results and cause them to differ materially from those expressed or implied by the forward-looking statements in this news release, including, but not limited to, disappointing market responses to current or future products or services; prolonged, new, or exacerbated disruption of our supply chain; the further or prolonged disruption of new product development; production or distribution disruption or delays in entry or penetration of sales channels due to inventory constraints, competitive factors, increased transportation costs or interruptions, including due to weather, flooding or fires; prototype, parts and material shortages, particularly of parts sourced from limited or sole source providers; determinations by third party controlled distribution channels, including Amazon, not to carry or reduce inventory of the Company’s products; determinations by advertisers or social media platforms, or legislation that prevents or limits marketing of some or all Byrna products; the loss of marketing partners; increases in marketing expenditure may not yield expected revenue increases; potential cancellations of existing or future orders including as a result of any fulfillment delays, introduction of competing products, negative publicity, or other factors; product design or manufacturing defects or recalls; litigation, enforcement proceedings or other regulatory or legal developments; changes in consumer or political sentiment affecting product demand; regulatory factors including the impact of commerce and trade laws and regulations; and future restrictions on the Company’s cash resources, increased costs and other events that could potentially reduce demand for the Company’s products or result in order cancellations. The order in which these factors appear should not be construed to indicate their relative importance or priority. We caution that these factors may not be exhaustive; accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. Investors should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, (“Risk Factors”) in the Company’s most recent Form 10-K and Part II, Item 1A (“Risk Factors”) in the Company’s most recent Form 10-Q, should understand it is impossible to predict or identify all such factors or risks, should not consider the foregoing list, or the risks identified in the Company’s SEC filings, to be a complete discussion of all potential risks or uncertainties, and should not place undue reliance on forward-looking information. The Company assumes no obligation to update or revise any forward-looking information, except as required by applicable law.

    Investor Contact:
    Tom Colton and Alec Wilson
    Gateway Group, Inc.
    949-574-3860
    BYRN@gateway-grp.com

    -Financial Tables to Follow-

             
    BYRNA TECHNOLOGIES INC.
    Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
    (Amounts in thousands except share and per share data)
    (Unaudited)
             
        For the Three Months Ended
        February 28
          2025       2024  
    Net revenue   $ 26,190     $ 16,654  
    Cost of goods sold     10,266       7,015  
    Gross profit     15,924       9,639  
    Operating expenses     14,228       9,803  
    INCOME (LOSS) FROM OPERATIONS     1,696       (164 )
    OTHER INCOME (EXPENSE)        
    Foreign currency transaction loss     (80 )     (58 )
    Interest income     186       280  
    Loss from joint venture     –       (42 )
    Other income (expense)     –       1  
    INCOME (LOSS) BEFORE INCOME TAXES     1,802       17  
    Income tax expense     (140 )     –  
    NET INCOME (LOSS)   $ 1,662     $ 17  
             
    Foreign currency translation adjustment for the period     (130 )     (115 )
    Unrealized gain on marketable securities     60       –  
    COMPREHENSIVE INCOME (LOSS)   $ 1,592     $ (98 )
             
    Basic net income (loss) per share   $ 0.07     $ 0.00  
    Diluted net income (loss) per share   $ 0.07     $ 0.00  
             
    Weighted-average number of common shares outstanding – basic     22,587,099       22,035,249  
    Weighted-average number of common shares outstanding – diluted     24,098,635       22,838,827  
             
             
    BYRNA TECHNOLOGIES INC.
    Condensed Consolidated Balance Sheets
    (Amounts in thousands, except share and per share data)
             
        February 28   November 30,
          2025       2024  
        Unaudited    
    ASSETS        
    CURRENT ASSETS        
    Cash and cash equivalents   $ 7,669     $ 16,829  
    Marketable Securities     11,620       8,904  
    Accounts receivable, net     2,900       2,630  
    Inventory, net     23,182       19,972  
    Prepaid expenses and other current assets     3,441       2,623  
    Total current assets     48,812       50,958  
    LONG TERM ASSETS        
    Deposits for equipment     3,669       2,665  
    Right-of-use-asset, net     2,218       2,452  
    Property and equipment, net     4,651       3,408  
    Intangible assets, net     3,273       3,337  
    Goodwill     2,258       2,258  
    Deferred tax asset     5,468       5,837  
    Other assets     689       1,007  
    TOTAL ASSETS   $ 71,038     $ 71,922  
             
    LIABILITIES        
    CURRENT LIABILITIES        
    Accounts payable and accrued liabilities   $ 11,183     $ 13,108  
    Operating lease liabilities, current     572       539  
    Deferred revenue, current     482       1,791  
    Total current liabilities     12,237       15,438  
    LONG TERM LIABILITIES        
    Deferred revenue, non-current     11       17  
    Operating lease liabilities, non-current     1,963       2,098  
    Total liabilities     14,211       17,553  
             
             
    STOCKHOLDERS’ EQUITY        
    Preferred stock     —       —  
    Common stock     25       25  
    Additional paid-in capital     133,895       133,029  
    Treasury stock     (21,253 )     (21,253 )
    Accumulated deficit     (55,121 )     (56,783 )
    Accumulated other comprehensive loss     (719 )     (649 )
             
    Total Stockholders’ Equity     56,827       54,369  
             
    TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY   $ 71,038     $ 71,922  
             

    Non-GAAP Financial Measures

    In addition to providing financial measurements based on generally accepted accounting principles in the United States (GAAP), we provide an additional financial metric that is not prepared in accordance with GAAP (non-GAAP) with presenting non-GAAP adjusted EBITDA. Management uses this non-GAAP financial measure, in addition to GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes and to evaluate our financial performance. We believe that this non-GAAP financial measure helps us to identify underlying trends in our business that could otherwise be masked by the effect of certain expenses that we exclude in the calculations of the non-GAAP financial measure.

    Accordingly, we believe that this non-GAAP financial measure reflects our ongoing business in a manner that allows for meaningful comparisons and analysis of trends in the business and provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects.

    This non-GAAP financial measure does not replace the presentation of our GAAP financial results and should only be used as a supplement to, not as a substitute for, our financial results presented in accordance with GAAP. There are limitations in the use of non-GAAP measures, because they do not include all the expenses that must be included under GAAP and because they involve the exercise of judgment concerning exclusions of items from the comparable non-GAAP financial measure. In addition, other companies may use other non-GAAP measures to evaluate their performance, or may calculate non-GAAP measures differently, all of which could reduce the usefulness of our non-GAAP financial measure as a tool for comparison.

    Adjusted EBITDA

    Adjusted EBITDA is defined as net (loss) income as reported in our condensed consolidated statements of operations and comprehensive (loss) income excluding the impact of (I) depreciation and amortization; (ii) income tax provision (benefit); (iii) interest income (expense); (iv) stock-based compensation expense, (v) impairment loss, and (vi) one time, non-recurring other expenses or income. Our Adjusted EBITDA measure eliminates potential differences in performance caused by variations in capital structures (affecting finance costs), tax positions, the cost and age of tangible assets (affecting relative depreciation expense) and the extent to which intangible assets are identifiable (affecting relative amortization expense). We also exclude certain one-time and non-cash costs. Reconciliation of Adjusted EBITDA to net (loss) income, the most directly comparable GAAP measure, is as follows (in thousands):

          For the Three Months Ended
          February 28
            2025       2024  
    Net Income (Loss)   $ 1,662     $ 17  
               
    Adjustments:        
      Interest income     (186 )     (280 )
      Income tax expense     140       –  
      Depreciation and amortization     185       338  
    Non-GAAP EBITDA   $ 1,801     $ 75  
               
    Stock-based compensation expense     840       938  
    Severance/Separation/Officer recruiting     130       163  
    Non-GAAP adjusted EBITDA   $ 2,771     $ 1,176  
               

    1 See non-GAAP financial measures at the end of this press release for a reconciliation and a discussion of non-GAAP financial measures.

    The MIL Network –

  • MIL-OSI: STMicroelectronics details company-wide program to reshape manufacturing footprint and resize global cost base

    Source: GlobeNewswire (MIL-OSI)

    PR No: C3330C

    STMicroelectronics details company-wide program to reshape manufacturing footprint and resize global cost base

    • Increasing efficiency, automation, and AI will strengthen ST’s key technology R&D, design and high-volume assets for advanced manufacturing in Europe.
    • Planned investments over FY2025, 2026 and 2027 to focus on advanced manufacturing infrastructure in 300mm silicon, 200mm silicon carbide, and technology R&D, for the benefit of customers globally.
    • Company-wide program, including both the previously disclosed resizing of cost base and the reshaping of manufacturing footprint, expected to see up to 2,800 people leaving the company globally on a voluntary basis over 3 years, on top of normal attrition.
    • Confirmation of annual cost savings target in the high triple-digit million-dollar range exiting 2027.

    Geneva, April 10, 2025 – STMicroelectronics N.V. (“ST”) (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, today disclosed further elements of its program to reshape its global manufacturing footprint. This comes as part of the program announced in October 2024 to further strengthen ST’s competitiveness, solidify its position as a global semiconductor leader, and ensure the long-term sustainability of its model as an Integrated Device Manufacturer by leveraging strategic assets globally across technology R&D, design and high-volume manufacturing. 

    Jean-Marc Chery, President and CEO of STMicroelectronics said: “The reshaping of our manufacturing footprint announced today will future proof our Integrated Device Manufacturer model with strategic assets in Europe and improve our ability to innovate even faster, benefitting all our stakeholders. As we focus on advanced manufacturing infrastructure and mainstream technologies, we will continue to leverage all of our existing sites and bring redefined missions for some of them to support their long-term success. We are committed to managing this program responsibly, according to our long-established values, and exclusively through voluntary measures. The technology R&D, design, and high-volume manufacturing activities in Italy and France will continue to be central to our global operations and will be reinforced via planned investments in mainstream technologies”.

    Innovating and scaling up to increase efficiency across manufacturing operations

    As innovation cycles shorten, ST’s manufacturing strategy is evolving to accelerate the delivery of innovative, proprietary technologies and products at scale to customers globally, across automotive, industrial, personal electronics and communication infrastructure applications.

    The reshaping and modernization of ST’s manufacturing operations aim to achieve two main objectives: prioritizing planned investments towards future-ready infrastructure such as 300mm silicon and 200mm silicon carbide wafer fabs to enable them to reach a critical scale and maximizing the productivity and efficiency of legacy 150mm capabilities and mature 200mm capabilities. In parallel, ST plans to continue to invest in upgrading the technology used across its operations, deploying additional AI and automation for additional efficiency in technology R&D, manufacturing, reliability and qualification processes, with a continued focus on sustainability. 

    Strengthening ST’s manufacturing ecosystem

    Over the next three years, the reshaping of ST’s manufacturing footprint will design and strengthen ST’s complementary ecosystems: in France around digital technologies, in Italy around analog and power technologies and in Singapore on mature technologies. The optimization of these operations aim to achieve full capacity utilization and drive technological differentiation to compete globally. As announced previously, each of ST’s current sites will continue to play a long-term role within the company’s global operations. 

    Building 300mm silicon megafabs in Agrate and Crolles

    The Agrate (Italy) 300mm fab will continue to be scaled up, with the aim to become ST’s flagship high-volume manufacturing facility for smart power and mixed signal technologies. The plan is to double its current capacity to 4,000 wafers per week (wpw) by 2027, with planned modular expansions increasing capacity up to 14,000 wpw, depending on market conditions. As we increase our focus on 300mm manufacturing, the Agrate 200mm fab will refocus on MEMS.
    The Crolles (France) 300mm fab will be further cemented as the core of ST’s digital products ecosystem. The plan is to increase capacity to 14,000 wpw by 2027 with planned modular expansions increasing capacity up to 20,000 wpw, depending on market conditions. In addition, we will convert the Crolles 200mm fab to support Electrical Wafer Sorting high volume manufacturing and advanced packaging technologies, hosting activities that do not exist today in Europe. The focus will be on next-generation leading technologies including optical sensing and silicon photonics.

    Specialized Manufacturing and Competence Center for Power Electronics in Catania

    Catania will continue to serve as a center of excellence for power and wide-bandgap semiconductor devices. The development of the new Silicon Carbide Campus is progressing as planned, with production of 200mm wafers set to begin in Q4 2025, reinforcing ST’s leadership in next-generation power technologies. Our resources supporting Catania’s current 150mm and EWS capabilities will be refocused on 200mm silicon carbide and silicon power semiconductor production, including GaN-on-silicon, reinforcing ST’s leadership in next-generation power technologies.

    Optimizing Other Manufacturing Sites

    Rousset (France) will remain focused on 200mm manufacturing, with additional volumes reallocated from other sites enabling full saturation of existing manufacturing capacity for optimized efficiency.

    Tours (France) will remain focused on its 200mm silicon production line for select technologies, while other activities – including legacy 150mm manufacturing activities – will be transferred to different ST sites, and it will also remain a center of competence for GaN, mainly on epitaxy. The Tours site will also host a new activity: panel-level-packaging, one of the major enablers of chiplets, a technology for complex semiconductor applications that will be key for ST in the future.

    Ang Mo Kio (Singapore), ST’s high-volume fab for mature technologies, will remain focused on 200mm silicon manufacturing and will also host our consolidated global legacy 150mm silicon capabilities.

    Kirkop (Malta), ST’s high-volume test and packaging fab in Europe will be upgraded, with the addition of advanced automated technologies which will be key to support next-generation products.

    Workforce and skills evolution

    As ST reshapes its manufacturing footprint over the next three years, the workforce size and required skill sets will evolve. Advanced manufacturing will shift roles from legacy processes involving repetitive manual tasks to a stronger focus on process control, automation, and design. ST will manage this transition through voluntary measures, with a continued commitment to ongoing constructive dialogue and negotiations with employee representatives in accordance with applicable national regulations. Based on current projections, the program is expected to see up to 2,800 people leaving the company globally on a voluntary basis, on top of normal attrition. These changes are expected to occur mainly in 2026 and 2027. Regular updates will be provided to stakeholders as the program progresses. 

    About STMicroelectronics

    At ST, we are 50,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com.

    For further information, please contact:

    INVESTOR RELATIONS:
    Jérôme Ramel
    EVP Corporate Development & Integrated External Communication
    Tel: +41 22 929 59 20
    jerome.ramel@st.com

    MEDIA RELATIONS:
    Alexis Breton
    Corporate External Communications
    Tel: + 33 6 59 16 79 08
    alexis.breton@st.com

    Attachment

    The MIL Network –

  • MIL-OSI: Eviden signs a 50-million-euro contract to build Serbia’s National AI Factory

    Source: GlobeNewswire (MIL-OSI)

    Eviden will bring together a unique comprehensive set of AI capabilities – supercomputing power for AI, software layer and AI use-cases development

    Paris, France – April 10, 2025 – Eviden, the Atos Group business leading in digital, cloud, big data and security today announces the signature of a 50-million-euro contract with the Serbia’s Office for IT and eGovernment. Together, Eviden and the Serbian administration will deploy a National AI Factory – composed of an AI Center of Excellence and a leading AI-dedicated supercomputing platform – aiming to accelerate Serbia’s AI capabilities and foster innovation across key sectors while reinforcing its technological autonomy using European technologies.

    More than just a simple infrastructure, an AI Factory is an extensive and complete set of shared AI-dedicated assets – talents, expertise, software, hardware – to foster AI innovation and growth, to democratize its use and to drive successful large-scale projects. By providing all necessary resources with European technologies through this single contract, Eviden will empower Serbia to address the growing challenges and requirements of AI.

    This new National AI Factory, a first in the Balkan region, will integrate cutting-edge supercomputing resources, advanced software layers and specialized vertical expertise for use-case design and deployment. This dynamic ecosystem will be made accessible to Serbian public institutions, academic players and businesses in order to harness the power of AI and address critical challenges in health, energy, transportation and administration.

    To meet Serbia’s needs for computing power, Eviden will deploy its BullSequana XH3000 supercomputer, designed and manufactured in its French flagship factory. With up to 25 PetaFlops of computational power – the equivalent of 25 million billion operations per second – as well as 300 GPUs and 2.5 Petabytes of storage, this AI supercomputer will serve as the backbone of this AI Center of Excellence, providing the necessary computing power to develop and run innovative AI use cases.

    In addition to this AI-dedicated hardware, the project will see the implementation of Eviden’s BullSequana AI platform, designed to accelerate AI applications development. The Eviden software layer will integrate Mistral AI assets who brings its leading European GenAI models to help drive groundbreaking use cases.

    This combination of hardware and software capabilities will be complemented by a vertical AI expertise drawn from Eviden’s teams in France, Czech Republic and Serbian AI ecosystem. These AI specialists will bring their deep understanding of sector-specific needs, ensuring an effective application of AI to Serbia’s strategic sectors. They will also assist in recruiting and training engineers and academics across Serbia, ensuring the AI Center of Excellence becomes a self-sustaining hub for innovation.

    Mihailo Jovanovic PhD, Director of the Office for IT and eGovernment, Government of the Republic of Serbia said “This partnership with Eviden, Europe’s leading supercomputing and AI player, is a historic moment for our country’s digital future, demonstrating the spirit of Franco-Serbian cooperation. It is not just a technological leap but a statement of our commitment to foster innovation, advanced our economy and strengthen our position as regional leader in AI. This project is a key step towards implementing Serbia’s vision in accordance with “Leap into the Future – Serbia 2027” Program and plans for further modernization, digitalization, and the application of artificial intelligence.”

    Emmanuel Le Roux, Head of Advanced Computing, Eviden, Atos Group said “With its investment and current leading responsibility in the Global Partnership on AI, Serbia has been at the forefront of AI research and application in Europe. This one-of-a-kind project is yet another example of its commitment toward technological advanced and economic growth, while contributing to the strategic cooperation between France and Serbia for AI and reinforcing the country’s technological sovereignty. It underlines Eviden’s unique end-to-end positioning and demonstrates once again how Europe’s technology leaders can drive AI innovation while ensuring technological autonomy and sovereignty.”

    ***

    About Eviden1

    Eviden is a next-gen technology leader in data-driven, trusted and sustainable digital transformation with a strong portfolio of patented technologies. With worldwide leading positions in advanced computing, security, AI, cloud and digital platforms, it provides deep expertise for all industries in more than 47 countries. Bringing together 41,000 world-class talents, Eviden expands the possibilities of data and technology across the digital continuum, now and for generations to come. Eviden is an Atos Group company with an annual revenue of c. € 5 billion.

    About Atos

    Atos is a global leader in digital transformation with c. 78,000 employees and annual revenue of c. € 10 billion. European number one in cybersecurity, cloud and high-performance computing, the Group provides tailored end-to-end solutions for all industries in 68 countries. A pioneer in decarbonization services and products, Atos is committed to a secure and decarbonized digital for its clients. Atos is a SE (Societas Europaea) and listed on Euronext Paris.

    The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

    About Mistral AI

    Mistral AI is a pioneer company in generative artificial intelligence, empowering the world with the tools to build and benefit from the most transformative technology of our time. The company democratizes AI through high-performance, optimized, and cutting-edge open-source models, products and solutions. Headquartered in France and independent, Mistral AI defends a decentralized and transparent approach to technology, with a strong global presence in the United States, United Kingdom, and Singapore.

    Press contact

    Constance Arnoux – constance.arnoux@eviden.com – +33 6 44 12 16 35

    1 Eviden business is operated through the following brands: AppCentrica, ATHEA, Cloudamize, Cloudreach, Cryptovision, DataSentics, Edifixio, Engage ESM, Evidian, Forensik, IDEAL GRP, In Fidem, Ipsotek, Maven Wave, Profit4SF, SEC Consult, Visual BI, X-Perion.

    Eviden is a registered trademark. © Eviden SAS, 2025.

    Attachment

    The MIL Network –

  • MIL-OSI: CURRENC Group Inc. Regains Full Compliance with Nasdaq’s Continued Listing Rule

    Source: GlobeNewswire (MIL-OSI)

    SINGAPORE, April 10, 2025 (GLOBE NEWSWIRE) — CURRENC Group Inc. (Nasdaq: CURR) (“CURRENC” or the “Company”), a fintech pioneer empowering financial institutions worldwide with artificial intelligence (AI) solutions, today announced that on April 9, 2025, it received written notice from Nasdaq stating that the Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) has determined that for at least the last ten consecutive business days, the Company’s ordinary shares have maintained a minimum market value of publicly held shares (“MVPHS”) of $5,000,000 or greater, satisfying The Nasdaq Global Market’s continued listing requirement set forth in Listing Rule 5450(b)(1)(C) (the “Rule”). Accordingly, the Company has regained compliance with the Rule, and this matter is now closed by Nasdaq.

    Ronnie Ka Wah Hui, CEO of CURRENC, commented, “We are pleased to have regained compliance with the MVPHS Rule thanks to our team’s continued dedication to strengthening the foundation of our business. Maintaining our Nasdaq listing is vital to the Company’s strategy, offering credibility and exposure within the capital markets. We remain committed to disciplined execution and innovation, positioning CURRENC to drive long-term shareholder value.”

    About Currenc Group Inc.
    CURRENC Group Inc. (Nasdaq: CURR) is a fintech pioneer dedicated to transforming global financial services through artificial intelligence (AI). The Company empowers financial institutions worldwide with comprehensive AI solutions, including SEAMLESS AI Call Centre and other AI-powered Agents designed to reduce costs, increase efficiency and boost customer satisfaction for banks, insurance, telecommunications companies, government agencies and other financial institutions. The Company’s digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 global payment services, advancing financial access across underserved communities.  

    Forward-Looking Statements
    The information in this press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 with respect to CURRENC. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “aim,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk that investors may not receive the same benefits as an investor in an underwritten public offering, (ii) the risk that CURRENC’s securities may experience a material price decline due to market forces, (iii) the risk of product liability or regulatory lawsuits or proceedings relating to CURRENC’s business, (iv) the ability of CURRENC to comply with the continued listing standards of Nasdaq, (v) the ability to attract new partners, merchants and users and retain existing partners, merchants and users in order to continue to expand, (vi) the ability of CURRENC to fund its capital requirements through additional debt and equity financing under commercially reasonable terms and the risk of shareholding dilution as a result of additional capital raising, if applicable, (vii) the risk of cyber security or foreign exchange losses, (viii) the risk that CURRENC is unable to secure or protect its intellectual property, (ix) failure to maintain an effective system of internal control over financial reporting and to accurately and timely report CURRENC’s financial condition, results of operations or cash flows, and (x) those factors discussed in INFINT’s filings with the SEC and that are contained in the proxy statement relating to the Business Combination. You should carefully consider the foregoing factors and the other risks and uncertainties that will be described in the “Risk Factors” section of the proxy statement and other documents to be filed by CURRENC from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and while CURRENC may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. CURRENC does not give any assurance that it will achieve their respective expectations.

    Investor & Media Contact 
    CURRENC Group Investor Relations
    Email: investors@currencgroup.com 

    The MIL Network –

  • MIL-OSI: Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 09 04 2025] – (CGAML)

    Source: GlobeNewswire (MIL-OSI)

    FORM 8.3

    PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
    A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
    Rule 8.3 of the Takeover Code (the “Code”)

    1.        KEY INFORMATION

    (a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary clients)
    (b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
            The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    		 N/A
    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
            Use a separate form for each offeror/offeree    		 ADVANCED MEDICAL SOLUTIONS GROUP PLC
    (d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
    (e)   Date position held/dealing undertaken:
            For an opening position disclosure, state the latest practicable date prior to the disclosure    		 09 APRIL 2025
    (f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
            If it is a cash offer or possible cash offer, state “N/A”    		 N/A

    2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

    If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

    (a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

    Class of relevant security: 5p ORDINARY
      Interests Short positions
    Number % Number %
    (1)   Relevant securities owned and/or controlled: 4,775,000 2.1901    
    (2)   Cash-settled derivatives:        
    (3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
    TOTAL: 4,775,000 2.1901    

    All interests and all short positions should be disclosed.

    Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

    (b)      Rights to subscribe for new securities (including directors’ and other employee options)

    Class of relevant security in relation to which subscription right exists:  
    Details, including nature of the rights concerned and relevant percentages:  

    3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

    Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

    The currency of all prices and other monetary amounts should be stated.

    (a)        Purchases and sales

    Class of relevant security Purchase/sale Number of securities Price per unit
    5p ORDINARY PURCHASE 85,000 200.5533p

    (b)        Cash-settled derivative transactions

    Class of relevant security Product description
    e.g. CFD    		 Nature of dealing
    e.g. opening/closing a long/short position, increasing/reducing a long/short position    		 Number of reference securities Price per unit
    NONE        

    (c)        Stock-settled derivative transactions (including options)

    (i)        Writing, selling, purchasing or varying

    Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
    e.g. American, European etc.    		 Expiry date Option money paid/ received per unit
    NONE              

    (ii)        Exercise

    Class of relevant security Product description
    e.g. call option    		 Exercising/ exercised against Number of securities Exercise price per unit

    (d)        Other dealings (including subscribing for new securities)

    Class of relevant security Nature of dealing
    e.g. subscription, conversion    		 Details Price per unit (if applicable)
    NONE      

    4.        OTHER INFORMATION

    (a)        Indemnity and other dealing arrangements

    Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
    Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

    NONE

    (b)        Agreements, arrangements or understandings relating to options or derivatives

    Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
    (i)   the voting rights of any relevant securities under any option; or
    (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
    If there are no such agreements, arrangements or understandings, state “none”

    NONE

    (c)        Attachments

    Is a Supplemental Form 8 (Open Positions) attached? NO
    Date of disclosure: 10 APRIL 2025
    Contact name: MARK ELLIOTT
    Telephone number: 01253 376539

    Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

    The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

    The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

    The MIL Network –

  • MIL-OSI United Kingdom: Cuttlefish plan launched

    Source: United Kingdom – Government Statements

    News story

    Cuttlefish plan launched

    An action plan to support the cuttlefish fishery in English waters has been launched by Marine Management Organisation (MMO) following engagement with stakeholders.

    Cuttlefish is critical to the businesses of fishers working in ICES areas 7d and 7e, and there are concerns that stock levels are at risk of being over exploited.

    Work on the Channel Demersal Non-Quota Species Fisheries Management Plan (FMP) identified a need to better understand fishing impact on numbers and the health of stocks.

    Further engagement with stakeholders, including commercial fishing representatives, last year demonstrated that formal management measures would not be required right now and would risk causing economic harm to fishers on the south coast.

    After listening to stakeholder feedback, MMO fisheries managers developed the cuttlefish action plan to better monitor and collect data to help with future decisions on potential management, including testing technical measures to conserve stocks.

    The plan is an important part of the implementation of the Channel Demersal Non-quota species FMP published in December 2023.

    MMO has now:

    • Introduced a voluntary code of practice on trap and pot handling in English waters from the 6nm limit out to 200nm in ICES divisions 7d and 7e. This is designed to improve survival rates for cuttlefish eggs and development of juveniles
    • Launched three cuttlefish species identification cards to help fishers to correctly identify and report catches and landings of specific species of cuttlefish. Better species-specific data will support improved understanding of stocks levels and their health so future decisions can be made based on evidence.
    • Undertaken monitoring and market sampling to better understand cuttlefish catch composition.

    The full action plan can be read here or email sustainablefisheries@marinemanagement.org.uk

    Updates to this page

    Published 10 April 2025

    MIL OSI United Kingdom –

  • MIL-OSI Russia: Scientific Regiment. Architect Alexander Sokolov preserved and restored cultural heritage

    Translartion. Region: Russians Fedetion –

    Source: Saint Petersburg State University of Architecture and Civil Engineering – Saint Petersburg State University of Architecture and Civil Engineering –

    Alexander Sokolov

    Every day for almost 70 years, thousands of people pass between the main building of SPbGASU and the Technological Institute metro station. At one time, among them was the architect, dean of the urban planning faculty of LISI (now SPbGASU), the author of the project for this station (co-authored with A.K. Andreev) Alexander Mikhailovich Sokolov (1906-1984). It was largely thanks to him that the cultural heritage of Leningrad was preserved during the Great Patriotic War.

    Study and work

    Alexander Sokolov entered the preparatory course of the Institute of Civil Engineers (IGI, now SPbGASU) in 1920 after graduating from the Tikhvin Real School, where, according to historical sources, “training was thorough, especially in mathematics and physics,” and the Tikhvin Second Soviet Labor School of the 2nd level, where he studied art history as one of the main subjects. In Petrograd, he worked as an installer, then as a draftsman. At the same time, he began studying in the workshop of Professor I. A. Fomin at the Free Art School of the People’s Commissariat of Education of the RSFSR (Academy of Arts). Until 1923, he studied at two universities, and then gave preference to the Academy of Arts. He would return to LISI years later as a teacher.

    Famous projects of the architect

    Aleksandr Sokolov was forced to combine his studies with work. He worked as a foreman (leader of a group of workers) in the Leningrad Commercial Port Administration, as a draftsman at the construction of the I. I. Mechnikov Hospital, and as an assistant to the architect S. O. Ovsyannikov during the construction of the Krasnoye Znamya factory. As a student, he designed an administrative building that was built in 1923–1924 on the territory of the commercial port (it has not survived).

    Later, the architect’s famous works included projects for the Vyborg District Sound Cinema with 1,300 seats in Leningrad, the House of the Government of Abkhazia, the building of the All-Union Institute of Experimental Medicine in Moscow, ground pavilions of the Lenin Library metro stations in Moscow and Moskovskie Vorota in Leningrad, and a hotel for sailors in Murmansk.

    In the siege of Leningrad and after the war

    In 1941, Aleksandr Mikhailovich Sokolov was engaged in research work in the archives of the Pavlovsk Palace Museum. With the outbreak of the war, he took an active part in the evacuation of valuables from the palace and the shelter of the park sculptures. During the siege, he worked in the Inspectorate for the Protection of Monuments, where he took part in the work of the city commission to identify the damage caused to the architectural heritage of Leningrad. The sketches of facades and interiors and design work he made during this period played a major role in the revival of the city. In particular, Aleksandr Sokolov supervised the restoration of the Mariinsky Theater. In 1943, Sokolov was awarded the medal “For the Defense of Leningrad”, in 1946 – the medal “For Valiant Labor in the Great Patriotic War of 1941-1945”.

    In early 1944, the primary task was to develop master plans for the affected cities of the Leningrad, Novgorod and Pskov regions. This work was carried out by the workshop of the Leningrad Regional Department of Architecture and the Lenproekt and Lenoblproekt trusts. The architectural planning workshop of the latter was headed by Alexander Sokolov in 1944–1948. Among other things, he worked on the master plan for his native Tikhvin, every corner of which he had known since childhood.

    Lecturer, Dean, Professor of LISI

    In 1931, Alexander Mikhailovich Sokolov began teaching architectural design at the Faculty of Architecture of the Leningrad Institute of Municipal Construction (now SPbGASU). In 1943–1946, he headed the course “Introduction to Architecture”. In 1946, he defended his PhD dissertation on “Architectural Structures of Pavlovsk Park”. In 1962–1969, he held the position of Dean of the Faculty of Urban Planning. Then, until 1983, he was a professor at the Department of History and Theory of Architecture.

    Other materials of the project “Scientific Regiment”

    Engineer of the 3rd Belorussian Front

    The path of a volunteer: from front-line roads to space developments

    Ivan Solomakhin: “The most memorable battle is for this Devil’s Height!”

    Fiery Dnieper of the Hero of the Soviet Union Alexander Prygunov

    Bringing Victory Closer

    Fyodor Komal’s Front: From the First Minutes of War to Victory

    Junior Political Instructor Boris Gubanov: “The shells whistled, and the earth flew up nearby”

    Viktor Kvyatkovsky – radio operator-intelligence officer of the Baltic Fleet

    How Chief Architect Nikolai Baranov “Hid” Leningrad from the Enemy

    Architect Nikolay Khomutetsky: Four years on the front lines

    Semyon Shifrin thwarted the Nazis’ plans to leave Leningrad without water

    LISI in the post-war years

    Nineteen-year-old machine gunner stormed Berlin

    Abdulla Mangushev: Four Years at the Front and a Life in Science

    The Zazersky architects built and defended the city on the Neva

    LISI graduate Mikhail Zherbin is a design engineer and composer

    He went from being a technical lieutenant to a galaxy of mathematicians

    Konstantin Sakhnovsky: from a cadet of the Russian Empire to an academician of the USSR

    Military architect of the front line of defense and engineering reconnaissance

    A world-renowned scientist, an outstanding engineer and a national champion

    An outstanding urban planner who lived and worked in besieged Leningrad

    Scientific Regiment. Projects of the architect Sergey Evdokimov: from defensive structures and city restoration to metro stations

    Scientific Regiment. Volunteer Mikhail Laletin: “After the front – to a university, and then, perhaps, to become an officer”

    Please note: This information is raw content directly from the source of the information. It is exactly what the source states and does not reflect the position of MIL-OSI or its clients.

    MIL OSI Russia News –

  • MIL-OSI Russia: At a meeting of the presidium of the government commission headed by Marat Khusnullin, the situation in housing construction was discussed

    Translartion. Region: Russians Fedetion –

    Source: Government of the Russian Federation – An important disclaimer is at the bottom of this article.

    Deputy Prime Minister Marat Khusnullin held a meeting of the presidium (headquarters) of the Government Commission on Regional Development, where they discussed issues of housing and road construction, and comprehensively examined key tasks within the framework of the national project “Infrastructure for Life”.

    “On the instructions of the President of Russia Vladimir Vladimirovich Putin, we, together with the Ministry of Construction, DOM.RF and the regions, are constantly monitoring the situation in housing construction and mortgage lending. In the first three months, according to preliminary data from the regions, housing commissioning amounted to 31.6 million square meters, which is 7% more than last year. Individual housing construction shows particularly impressive results – 24.6 million square meters, which is 20% more than the same period last year. Thanks to the record figures of previous years, we have formed a good reserve for the near future. However, due to the current difficult situation, we already see certain risks of a decrease in the rate of housing commissioning in the future, and it is necessary to begin working systematically to prevent them,” said Marat Khusnullin.

    The meeting of the headquarters also raised issues of road activities. The level of contracting today is 85.6%, cash execution – 16.9%. The Deputy Prime Minister recalled that a six-year plan for road activities has been approved, aimed at achieving target indicators for the regulatory condition of federal and regional roads, backbone roads and agglomerations. By the end of 2030, at least 50 bypasses of populated areas on federal and regional highways will be built.

    In his report, Minister of Construction and Housing and Public Utilities Irek Faizullin spoke about the comprehensive work being carried out by the Ministry of Construction to reduce the procedures of the investment and construction cycle, and drew the attention of the regions to the importance of bringing regional legislation into line with federal legislation.

    “The tasks set by the President of Russia in Decree No. 309 to reduce the procedures of the investment and construction cycle are included in the new national project “Infrastructure for Life” and the federal project “New Construction Rhythm” included in it. Currently, active work is underway together with the regions to improve the efficiency of urban planning standards taking into account the current level of human mobility, as well as the provision of specialized and public transport services. In order to speed up the construction of OKS, the subjects of the Russian Federation can specify and supplement the requirements for the placement of social infrastructure facilities taking into account regional and local characteristics,” said Irek Faizullin.

    The head of the Ministry of Construction also reported that the department quarterly updates the duration of the investment and construction cycle in the regions based on eight groups of criteria. These include the terms of the implementation of the project for the construction of capital construction projects (CCP), the provision of a land plot, the collection of initial data for design, the examination of design documentation, the issuance of permits for construction and commissioning, passing state construction supervision, cadastral registration and registration of rights, as well as regional requirements.

    Representatives of the Prosecutor General’s Office also took part in the meeting. Marat Khusnullin expressed gratitude to the employees of the supervisory agency for their systematic support and close attention to the development of the construction industry. He noted that productive interaction with the prosecutor’s office has become a key factor in the implementation of many strategic decisions to improve the construction sector and shared construction in particular.

    Special attention was paid to the issue of protecting the rights of equity holders who suffered from the actions of unscrupulous developers. The meeting participants discussed current mechanisms for restoring citizens’ rights and measures to prevent similar situations in the future.

    During the meeting, issues of infrastructure development of regions using the mechanism of treasury infrastructure loans were also discussed.

    In addition, representatives of the Ministry of Transport, as well as Primorsky Krai, the Udmurt Republic, Irkutsk, Omsk, Moscow and Novosibirsk regions, made reports at the meeting.

    Please note: This information is raw content directly from the source of the information. It is exactly what the source states and does not reflect the position of MIL-OSI or its clients.

    MIL OSI Russia News –

  • MIL-OSI United Nations: Preventable ‘meningitis belt’ deaths targeted in health agency action plan

    Source: United Nations 2

    Health

    Millions of deaths could be avoided from meningitis if countries are able to adopt new guidelines designed to diagnose and treat the disease more effectively, the UN World Health Organization (WHO) said on Thursday. 

    People anywhere, at any age can be infected with meningitis, which is transmitted through respiratory secretions or droplets in close human contact. Low and middle-income nations are worst-affected.  

    The so-called “meningitis belt” in sub-Saharan Africa sees most cases and outbreaks. It stretches from Senegal and The Gambia in the west of the continent all the way to Ethiopia in the east.  

    The most dangerous form of the disease, bacterial meningitis, can kill within just 24 hours – and one in six people dies once infected.

    “Every family who has had a meningitis case knows about what fear this disease can bring,” said Dr Marie-Pierre Preziosi, WHO Team Lead for Meningitis and R&D Blueprint.

    Life sentence

    Around 20 per cent of people who contract bacterial meningitis develop long-term complications, including disabilities with a devastating, life-long impact, WHO said in a statement.

    Extra attention must be paid to vaccination coverage to avoid critical problems including impairment of brain function, warned Dr Tarun Dua, WHO Unit Head for Brain Health, speaking to journalists at the launch of the new guidelines.

    Class divide 

    Hearing loss is just one side-effect of the disease; it is often particularly harmful for children whose education suffers. But if it can be detected quickly as per the new WHO guidelines “you can provide treatment and the child can be well included” at school and in society”, Dr. Dua explained.

    A cluster of three or four cases amongst schoolchildren can be treated with antibiotics but only if vaccination levels are high, according to Dr Lorenzo Pezzoli, WHO Team Lead for Meningitis and Epidemic Bacterial Diseases.

    Worth a shot 

    But many countries lack the means to provide vaccine protection to ensure collective immunity against many diseases, not only meningitis. In addition, they also lack the advanced technology required to diagnose the disease in the first place, which isn’t as easy as a COVID-19 swab test.

    “You need to insert the needle in the spine and test the liquid that comes out,” Dr Pezzoli said, highlighting the difficulty facing many low-income countries held back by poor health facilities.

    In a growing number of countries impacted by emergencies crisis or conflict, people cannot get the treatment they need as quickly as they should, creating “fertile grounds for meningitis epidemics”, said Dr Pezzoli, who added that his two-year-old son has had his jab for the disease.  

    The UN health agency guidelines form part of its efforts to eradicate meningitis by 2030. It works with partners including the MenAfrinet network to support countries collect and analyze high quality disease surveillance data. This enables monitoring the impact of control strategies including the Meningitis A vaccine.

    Prevention is “the most important piece of the puzzle”, Dr Pezzoli insisted. 

    MIL OSI United Nations News –

  • MIL-OSI: Welnax BioClear Reviews: DO NOT Spend A Dime Till You Have Read This Eyeopener Report!

    Source: GlobeNewswire (MIL-OSI)

    ORLANDO, Fla., April 10, 2025 (GLOBE NEWSWIRE) — Are you tired of dealing with stubborn nail fungus that just won’t go away? Have you tried countless creams, pills, or treatments that promise results but fail to deliver? Are you looking for a safe, painless, and effective solution to restore the health of your nails? Nail fungus is a common yet often embarrassing condition affecting millions worldwide. Characterized by thick, discolored, and brittle nails, it can lead to discomfort and a lack of confidence when displaying one’s feet. Traditional treatments, including topical antifungals and oral medications, can be ineffective and may lead to unwanted side effects.

    Fortunately, the Welnax BioClear offers a revolutionary solution to this persistent problem, using advanced low-level laser therapy (LLLT) to target and eliminate nail fungus at its source. Welnax not only promotes healthy nail growth but also boosts the immune system to help prevent future infections.

    In recent years, the demand for effective, drug-free solutions for nail fungus has surged, as more individuals seek safe and convenient treatments. The Welnax BioClear stands out in a crowded market by providing a clinically proven method that can be used in the comfort of one’s home. Users report significant improvements in the condition of their nails after just a few sessions, with many expressing reliefs from the embarrassment and discomfort associated with nail fungus.

    According to many research findings and expert reports, Welnax Bioclear has been referred to as the “Ultimate Toenail Fungus Cure” in the United States of America, Canada and Australia. Unlike messy creams or medications with potential side effects, Welnax is designed to be gentle, effective, and easy to use, with just seven minutes a day, you can experience visible improvements in nail health within weeks.

    In this review, we will analyze every aspect of the Welnax BioClear, including its operation and real consumers reports and complaints experiences. In order for you to determine whether Welnax is the game-changer you’ve been waiting for in your quest for healthier nails, let us give you an unbiased analysis of everything it has to offer. Stay tuned as we explore the details and discover what makes Welnax BioClear the best solution for nail fungus in the United States.

    What Is Welnax (Welnax BioClear Reviews)

    Welnax BioClear is a legitimate at-home device designed to help improve the appearance of nails affected by fungal infections. Welnax offers an innovative solution using clinically proven low-level laser therapy to help restore the natural appearance of nails. Every review confirms that Welnax features 15 high-performance lasers that penetrate deep into the nail bed, targeting and breaking down fungal cells at their root. With regular use, users will see noticeable improvements in nail health, including the restoration of clear, smooth nails.

    Developed by leading podiatrists and dermatologists, the Welnax BioClear is a safe, drug-free and reliable solution suitable for anyone struggling with nail fungus. Welnax BioClear epitomizes a pioneering breakthrough in fungus-fighting technology, utilizing a groundbreaking, medical-grade light therapy to eradicate fungal infections at their source. All reviewers revealed that Welnax BioClear has been recognized for its superior performance and ultimate reliability thereby making it the best device for curing nail fungal infections among many customers in the United States, UK, Australia and Canada.

    In rigorous testing against some of the worst cases of nail infections, Welnax BioClear has delivered exceptional outcomes. Real users, including Mark, who battled a seven-year-long infection, Susan, a 62-year-old who canceled a potentially invasive surgery, and Jason, an athlete sidelined by painful fungus, have all experienced revolutionary improvements within weeks of daily, seven-minute sessions. With an impeccable star rating, Welnax BioClear commands an excellent performance from majority of the consumers that have used it, these success stories reinforce the Welnax’s ability to destroy fungal growth and revive the natural clarity and strength of the nails indicating that even the most chronic infections can be treated.

    Many Welnax reviews say that the Welnax BioClear is, without doubt, the most affordable and best nail fungus solution with an array of very incredible features and functions. The Welnax BioClear has 4.97-star ratings given by the consumers of Canada & USA for its superior low-level laser therapy technology, reliability, and noninvasive treatment, which unequivocally make it the most efficient and reliable device for toenail fungus device on the market in the USA and Canada.

    Engineered with optimal performance and convenience in mind, Welnax BioClear offers a non-invasive, risk-free alternative to costly treatments and harsh prescription medications. Its lightweight and intuitive model enables quick, at-home sessions that fit seamlessly into busy lifestyles. With no adverse side effects, no need for chemical applications, and a promise to wipe out infections where they hide, Welnax BioClear has become a dependable ally for those tired of ineffective creams and prolonged treatment sessions. Welcome to the future of nail care and reclaim the confidence of healthy, clear nails with Welnax BioClear.

    CLICK HERE TO BUY YOUR WELNAX BIOCLEAR FROM THE OFFICIAL WEBSITE AT MASSIVE DISCOUNT TODAY

    What Are The Unique Features of Welnax BioClear (Welnax BioClear Reviews)

    • Advanced-Grade Light Therapy Technology: Welnax BioClear uses improved, advanced -grade light therapy that releases specific wavelengths to combat fungal cells deep within the nail bed. This feature guarantees that the light energy is targeted precisely on the infected area, penetrating through the nail’s surface layers. The technology is formulated to destroy fungus, offering an approach that directly tackles the source of the infection. Its accuracy in wavelength selection is a key technical attribute of the device.
    • Non-Invasive and Drug-Free Operation: One of the most outstanding features of Welnax BioClear is its non-surgical, drug-free design. Welnax is designed to provide effective treatment without chemical agents or oral medications, removing the risk of side effects associated with traditional treatments. The system functions entirely through light therapy, making it a safe choice for users with sensitive skin or allergies. This design underscores its commitment to delivering a soothing yet powerful treatment solution.
    • Deep Penetration Capability: A great feature of Welnax BioClear is its ability to penetrate deep into the nail bed, intercepting fungal infections beneath the surface. Unlike conventional creams that only treat the surface, the device’s focused light energy tackles the infection at its core. This deep penetration guarantees that the treatment interacts directly with the affected tissue, thereby improving the potential for reviving nail health. The accuracy of this capability underlines the product’s technical sophistication.
    • User-Friendly Interface and Operation: Welnax BioClear is designed with a simple, user-friendly interface that streamlines the treatment process. Its one-button operation and automated timer enable users to activate therapy sessions with minimal effort. This convenience guarantees that the device can be effortlessly integrated into daily routines, even for those with busy lifestyles. The controls reflect thoughtful engineering aimed at easing usability without compromising technological performance.
    • Compact and Portable Design: The Welnax’s compact design is another remarkable feature that promotes its practicality. Welnax BioClear is designed to be compact and portable, enabling users to perform treatments at home or while traveling. Its durable construction ensures that it remains trusted over long periods of use. The portability does not compromise its productivity, making it a suitable choice for individuals looking for a high-performance treatment tool easily integrated into various environments.
    • Convenient At-Home Use: With the Welnax BioClear, users can perform their treatments in the comfort of their own homes. This convenience eliminates the need for costly and time-consuming visits to dermatologists or podiatrists for laser treatments, making it an accessible solution for everyone. The Welnax is designed for easy use, allowing individuals to incorporate it into their daily routines effortlessly.
    • Positive User Testimonials: Many users have reported significant improvements in their nail health after using the Welnax BioClear. Testimonials highlight quick results, increased confidence, and the ability to wear sandals and open-toed shoes without embarrassment. The positive feedback from satisfied customers underscores the effectiveness of the Welnax.

    Does the Welnax BioClear Really Work? (Welnax Reviews)

    Welnax BioClear works exceptionally by utilizing advanced low-level laser therapy (LLLT) to effectively treat nail fungus. Welnax has rapidly gained attention for its ability to tackle stubborn nail fungus with an innovative, medical-grade light therapy method. Built to penetrate deep into the nail bed, the Welnax tackles the fungal cells at their very core—something conventional topical creams or oral medications often fail to address. This accuracy-focused approach ensures that even the most chronic infections can be tackled, and users have reported visible improvements within weeks of consistent use.

    In practical applications, Welnax BioClear has shown its worth by revitalizing nails that once suffered from thick, discolored, and brittle fungal infections. The Welnax BioClear’s model is based on clinically inspired technology that not only destroys the fungal cells but also improves the growth of healthier nail tissue. This dual action; eliminating the infection and promoting natural regrowth has dazzled users who have seen a dramatic reversal in their nail conditions, setting it apart from other treatments that only offer temporary or superficial relief.

    Ultimately, many glowing positive feedbacks of Welnax BioClear indicate a high level of trust and satisfaction among its users. All reviewers revealed Welnax BioClear has also received several good customer reviews where they are being complimented for its ease of use and performance. The incorporation of deep penetration capability, non-invasive and drug-free operation, and an easy-to-use design makes it an unmatched choice for those frustrated with futile treatments. While individual results may vary, overwhelmingly positive feedback underlines that Welnax truly works, delivering a remarkable, science-approved remedy for restoring nail health and confidence.

    Why Is Welnax Better Than Similar Products on the Market? (Welnax Reviews)

    Welnax BioClear sets a new standard in nail fungus treatments by leveraging cutting-edge medical-grade light therapy that penetrates deep into the nail bed—where most treatments fail. Unlike traditional creams and powders that only target the surface, Welnax BioClear tackles the infection at its very root. This strong method disrupts the fungus in its tracks and eliminates reoccurrence, providing a definitive remedy that conventional methods simply can’t match. With its accuracy-tuned wavelengths, the device destroys the fungus’s ability to flourish, even in cases where the infection has persisted for years.

    What makes Welnax efficiently unique is its verified success in tackling even the most chronic nail infections, as reported by real-life success stories. Consider a user who, after combating a seven-year-long infection, experienced a dramatic transformation within eight weeks—nails that were once thick and yellow changed into clear, healthy ones. Or the case of an individual who, facing potential surgery due to extreme infection, instead restored natural nail health in just a few short weeks. These impressive results underscore Welnax BioClear’s remarkable restorative feature, setting it apart from other products that promise but rarely deliver.

    Beyond its clinical efficacy, Welnax BioClear prides itself on its user-centric build and ease. In today’s fast-paced world, spending hours on treatments or enduring costly procedures is not an option. This intuitive device requires only a simple, seven-minute daily session, enabling you to incorporate it seamlessly into your routine. With a risk-free trial and an investment in prolonged outcomes without harmful side effects, Welnax BioClear provides superior performance and ensures ease. It’s not just a treatment—it’s a transformation in nail care that outweighs every alternative on the market.

    What Are The Powerful Benefits of the Welnax BioClear

    • Efficient Elimination of Fungal Infections: Welnax BioClear provides a significant benefit by effectively destroying fungal infections deep within the nail bed. Its medical-grade light therapy enters beyond the surface, directly tackling fungal cells at their root. This approach disrupts the fungus’s growth cycle and prevents further spread of the infection. For instance, one user, Mark, who had battled a seven-year-long infection, reported that after just eight weeks his nails were completely clear. Such firsthand experiences show how the product combats the underlying issue, resulting in visibly healthier nails and renewed confidence in nail care.
    • Encourages Natural Nail Regrowth: By destroying the harmful fungal cells, Welnax BioClear builds an optimal environment for natural nail regrowth. This benefit is beyond merely concealing the symptoms—by eliminating the infection, the device enables new, healthy nail tissue to form and thrive. A customer named Susan, for example, canceled a recommended surgery after witnessing her thick, discolored nails gradually become thinner and healthier over 12 weeks. This natural regrowth process enhances the nails’ aesthetic appeal and improves their strength and resilience, paving the way for a permanent solution to chronic fungal problems.
    • Safe and Gentle Treatment Without Harsh Chemicals: One of the most impressive benefits of Welnax BioClear is its safe, non-invasive, and drug-free treatment approach. Users can avoid the side effects and potential risks linked with harsh toxins, creams, or oral medications. Verified customer reviews emphasize that the treatment is entirely gentle, even for those with sensitive skin or allergies. One satisfied user mentioned how the painless, light-based therapy allowed them to experience significant improvements without discomfort or adverse reactions. This exclusive approach makes it a reliable option for many, guaranteeing that nail care remains both effective and safe over extended periods.
    • Convenience and Ease-of-Use for At-Home Therapy: Welnax BioClear is crafted for seamless home use, enabling users to incorporate effective nail care into even the strictest of schedules. Its intuitive interface and quick 7-minute daily sessions mean that you don’t need to visit a clinic or engage in time-consuming treatments. Many customers, including those who once juggled multiple appointments, appreciate the simplicity of the process—just a few minutes a day from the comfort of home can yield positive results. This convenience factor has been recurring in customer reviews, with users raving about the product for its ease of use and consistent performance that fits seamlessly into everyday routines.
    • Cost-Effective Investment for Long-Term Nail Health: Welnax BioClear represents a cost-effective solution for those looking for a lasting solution for nail fungus. Unlike recurring costs for creams, pills, or costly clinical treatments, this device offers a one-time investment that delivers beautiful results. Customers have noted significant savings over time, as the need for supplementary treatments decreases with consistent use. For instance, many users have expressed their satisfaction with the product’s affordability compared to the high costs of conventional therapies. This financial perk, coupled with the guarantee of improved nail health, makes it an attractive and smart investment for long-term care.
    • Clinically Proven and Consistent Results for Enhanced Confidence: Designed on clinically inspired technology, Welnax BioClear provides reliable outcomes, which have been certified by numerous user testimonials. Consistency in productivity indicates that regular users can expect gradual improvements in nail appearance and general health. For example, an athlete named Jason reported a complete turnaround after 10 weeks, enabling him to resume running without discomfort. Such consistent results not only revive nail integrity but also boost self-esteem. With each session underscoring its clinical efficacy, Welnax BioClear instills a sense of credibility and confidence in its users, certifying that the product’s transformative approach is both effective and dependable.

    Why Should I Buy the Welnax BioClear (Welnax Reviews)

    The Welnax is an outstanding solution for anyone battling with persistent toenail fungus. Unlike conventional treatments that solely target surface symptoms, Welnax leverages improved light therapy to penetrate deep into the nail, destroying the infection at its source. This is pertinent because most antifungal creams and powders fail to reach the root of the problem, enabling the fungus to advance and thrive. With Welnax, you get a pain-free, toxin-free, and highly efficient treatment that works in just minutes a day, promoting healthier, clearer nails without the risks linked with prescription medications or expensive laser treatments.

    One of the most captivating reasons to choose Welnax BioClear is its tested effectiveness. Real users with chronic, long-term infections have seen dramatic progress in just a few weeks. Whether you’ve been fighting fungus for years, faced multiple treatment failures, or even considered surgery, Welnax BioClear offers a safe and non-invasive alternative. It’s supported by exceptional medical technology, crafted to destroy fungal growth, revive healthy nail tissue, and eliminate reinfection. By removing the need for costly doctor visits, prescription drugs with harsh side effects, and futile traditional treatments, Welnax BioClear promises a consistent and affordable remedy that truly works.

    Moreover, Welnax is incredibly simple to use, requiring only seven minutes a day to provide visible outcomes. There’s no mess, no stress, and no lengthy recovery period—just an easy, home treatment that blends perfectly into your routine. Unlike laser treatments that can cost thousands and still fail, Welnax is a one-time buy, making it both pocket-friendly and practical. Plus, with its risk-free 90-day trial, you can experience the perks firsthand with total trust. Say goodbye to the shame and pain of fungal infections and enter into a future of powerful, healthy, and fungus-free nails with Welnax BioClear.

    CLICK HERE TO BUY YOUR WELNAX BIOCLEAR FROM THE OFFICIAL WEBSITE AT MASSIVE DISCOUNT TODAY

    How to Use Welnax BioClear (Welnax BioClear Reviews)

    Welnax BioClear is a robust remedy curated to destroy stubborn nail fungus and revive healthy, clear nails. Follow these three simple steps to maximize its effectiveness:

    • Prepare Your Nails: Start by washing and drying your hands or feet thoroughly to take out dirt and moisture. Trim your nails short and tenderly file the affected areas to help the solution enter deeper. Proper preparation guarantees the treatment reaches the root of the infection.
    • Apply Welnax BioClear: Using the right applicator, apply a small amount of the solution directly onto the affected nails, covering the whole surface and surrounding cuticle. Massage it calmly to improve absorption. For best results, apply twice daily—morning and night.
    • Stay Consistent & Monitor Progress: Fungal infections take time to heal, so consistency is paramount. With consistent use, you’ll notice improvements within weeks as discolored, brittle nails grow healthier. Maintain good hygiene, wear breathable footwear, and avoid damp environments to prevent reinfection.

    Is the Welnax BioClear Safe? (Welnax BioClear Reviews)

    Yes, using the Welnax BioClear at home is very safe. Furthermore, Welnax is legit. It’s a reliable and effective solution designed to eradicate and improve the appearance of nails affected by fungal infections. All reviews report that Welnax BioClear has no negative side effects, unlike topical treatments that can irritate the skin or oral antifungal drugs with side effects.

    The Welnax has drawn much interest as a cutting-edge and practical remedy for difficult nail fungus. Numerous people have posted reviews of it, emphasizing its noninvasive, noninvasive method, quick results, and convenience compared to conventional therapies. Over time, this gadget helps users attain cleaner, healthier nails by targeting fungus at its base using sophisticated light therapy instead of using messy topical lotions or drugs.

    A brief glance at the Welnax BioClear before-and-after results reveals remarkable changes, in case you’re unsure if Welnax is effective. Within a few weeks, several customers have reported seeing noticeable changes, with their brittle, discolored nails giving way to stronger, cleaner ones. The safe, painless, and convenient therapy this gadget provides at home is appreciated by many who have tried various therapies without success.

    Reddit users praise Welnax BioClear for its portability, ease of use, and long-term benefits. With no adverse effects, it’s a top choice. Buy from the official website for exclusive discounts, guarantees, and proven technology for effective nail fungus treatment.

    CLICK HERE TO BUY YOUR WELNAX BIOCLEAR FROM THE OFFICIAL WEBSITE AT MASSIVE DISCOUNT TODAY

    Is Welnax BioClear a Scam or Legit?

    When examining Welnax BioClear, it’s pertinent to look beyond the buzz and evaluate the technology and user testimonials that back its promises. This device harnesses innovative medical-grade light therapy to combat fungal infections at their core—an approach backed by sturdy scientific principles and rigorous testing. Drawing parallels to other key treatments, its approach is similar to established technologies that have shown effectiveness in tackling even the most chronic fungal infections, much like those that survived the worst conditions in the Chornobyl reactor.

    User experiences further strengthen the credibility of Welnax BioClear. Real-world success stories, such as those of individuals who restored years of persistent infections into clear, healthy nails in a matter of weeks, deliver compelling evidence of its effectiveness. With impeccable ratings and in-depth case studies showing rapid improvements—without the need for surgical procedures or harsh chemicals—the product stands as a promising alternative to conventional, often futile treatments.

    Ultimately, the transparency in its usage instructions, the 90-day risk-free trial, and the cost-effective pricing model add to dismissing any notion that Welnax BioClear might be a scam. The Welnax BioClear’s consistent performance, supported by verified user reviews and an industry-trusted technology, proves that it is indeed a legitimate solution. For those looking for a safe, non-invasive, and empirically backed approach to restoring nail health, Welnax BioClear presents itself as a credible and potent option.

    Who Needs the Welnax BioClear?

    • Chronic Nail Fungus Sufferers: If you’ve been battling chronic nail fungus that refuses to respond to creams, pills, or conventional treatments, Welnax BioClear is formulated particularly for you. Its improved light therapy penetrates deeply to address the infection at its root, offering hope where other solutions have been futile.
    • Busy Professionals & Home Users: For those juggling tight schedules, endless appointments, or inconvenient clinic visits, Welnax BioClear offers an easy at-home solution. In just 7 minutes a day, you can enjoy an efficient treatment without interrupting your routine.
    • Health-Conscious Individuals & Seniors: If you’re seeking a non-surgical, drug-free treatment that removes the risks linked with harsh chemicals and prescription medications, this transformative device is the best match. Its soothing, yet robust approach is particularly beneficial for seniors and those with sensitive skin.
    • Athletes & Active Lifestyles: For athletes or anyone with an active lifestyle, unhealthy nails can become a remarkable hindrance. Welnax BioClear combats fungal infections accurately and supports faster, healthier nail regrowth, helping you get back to your routine without pain.
    • Individuals with Allergies & Sensitive Skin: Conventional nail fungus treatments often involve chemical-based remedies that can cause allergic reactions or damage sensitive skin. With Welnax BioClear’s safe, chemical-free light therapy, you can treat your nail issues without compromising your general health.

    Pros (Welnax BioClear Reviews)

    • Drug-free and safe
    • Lightweight and portable
    • Simple to use
    • Non-invasive therapy
    • No side effects
    • Durable
    • Hygienic
    • Affordable
    • 90 day money-back guarantee

    Cons (Welnax Reviews)

    • Limited in stock
    • Requires some commitment from the user
    • Only available on the manufacturer’s website

    How Much Does Welnax BioClear Cost?

    Pricing options include:

    • One Welnax: $99.90 (Original: $199.90)
    • Two Welnax Bioclear: $149.90 (Save 62%)
    • 3 Devices: $179.90 (Save 70%)
    • 4 Devices: $199.90 (Save 75%)

    Where Can I Buy the Welnax BioClear?

    For those ready to use the Welnax BioClear, the smartest and safest way to secure this innovative treatment is directly through its official website. Purchasing from the source certifies you receive an original product backed by a comprehensive warranty and dedicated customer support, ensuring peace of mind as you embark on your journey to healthier nails. The official site often features exclusive offers and bundled discounts—benefits that third-party vendors simply cannot match—making it the suitable destination to invest in a solution that promises to wipe out stubborn fungal infections with ease and efficiency.

    CLICK HERE TO BUY YOUR WELNAX BIOCLEAR FROM THE OFFICIAL WEBSITE AT MASSIVE DISCOUNT TODAY

    Welnax Reviews Consumer Reports

    Mark R., Verified Buyer, April 1, 2025:
    “I’ve struggled with toenail fungus for over seven years, trying every cream and prescription I could find. Nothing worked—until I tried Welnax BioClear. After just four weeks of using it daily, I saw visible improvement. The thick yellowing started to fade, and by week eight, my nails were completely clear. I’m amazed at how quickly it worked, and it’s been life-changing for me. I finally feel confident enough to go barefoot again!”

    Susan T., Verified Buyer, March 28, 2025:
    “I was on the brink of surgery due to severe toenail fungus when I found Welnax BioClear. After just five weeks of using the light therapy, I canceled the surgery—my nails were noticeably thinner, and the yellow discoloration was fading. By twelve weeks, my nails were almost completely restored. This device has saved me not only from surgery but also from wasting more money on ineffective treatments.”

    Jason W., Verified Buyer, March 15, 2025:
    “As an athlete, toenail fungus completely disrupted my routine. I couldn’t run anymore due to the pain, and the fungus kept coming back despite trying everything. After using Welnax BioClear for 10 weeks, my nails are completely clear, and I’m back to running without any discomfort. It’s unbelievable how effective and simple this treatment is. Just seven minutes a day is all it took to change my life.”

    Frequently Asked Questions About Welnax BioClear (Welnax Reviews)

    How does Welnax BioClear work?

    Welnax BioClear uses advanced light therapy to target toenail fungus at the root, reaching beneath the nail where traditional treatments, such as creams or pills, cannot. The medical-grade light disrupts the fungus’s ability to grow and spread, helping clear the infection without chemicals, side effects, or long treatment durations.

    How long does it take to see results with Welnax BioClear?

    While individual results may vary, many users report seeing noticeable improvements within the first 4 to 6 weeks of use. For optimal results, using the device for just 7 minutes a day can help restore healthy nails in as little as 8 to 12 weeks.

    Can Welnax BioClear be used on other types of fungal infections?

    Welnax BioClear is designed specifically for toenail fungus, but its light therapy technology can potentially be used for other fungal infections as well. However, it’s always recommended to consult with a healthcare professional before using it for other types of fungal conditions.

    Does Welnax BioClear have any side effects?

    No, Welnax BioClear does not have any known side effects. Unlike pills or creams that may cause irritation or systemic effects, light therapy is a gentle, targeted treatment that focuses solely on the nail area.

    How long will I need to use Welnax BioClear?

    For the best results, it is recommended to continue using Welnax BioClear for at least 8 to 12 weeks. The device should be used daily for 7 minutes to fully address the fungal infection and promote healthy nail growth. Many users experience lasting improvements after consistent use.

    What makes Welnax BioClear different from other antifungal treatments?

    Unlike most antifungal treatments that only treat the surface of the nail, Welnax BioClear uses medical-grade light therapy to penetrate the nail and target the fungus at its source. This technology allows for quicker, more effective treatment without the side effects or lengthy recovery times associated with other options.

    Final Wrap on Welnax BioClear Reviews

    Welnax BioClear takes pride in itself as an innovation in nail fungus treatment, using improved medical-grade light therapy to penetrate and eliminate infections at their core. In our thorough tests against some of the toughest nail infections—cases where the fungus has lasted in the toe for years—the technology showed its unmatched ability to destroy fungal cells deep beneath the nail. Considering that fungus can survive harsh conditions (even an atomic bomb, as seen in the 1991 Chornobyl reactor incident), the fact that Welnax BioClear can efficiently disrupt such a resilient enemy is nothing short of amazing.

    Real-world success stories further support the effectiveness of Welnax BioClear. Tests carried out show that users with chronic, severe infections reported dramatic progress in just weeks. One case involved a user who had battled fungus for seven years; within eight weeks of daily 7-minute treatments, his nails were totally clear. Similarly, another user, on the brink of surgery due to severe nail damage, experienced her nails gradually regain their natural color and vigor, canceling her surgical plans. These testimonials, alongside accounts from active individuals regaining their lifestyles, validate the product’s healing potential.

    In conclusion, Welnax BioClear revolutionizes the approach to combating nail fungus by providing a non-invasive, stress-free remedy that penetrates the nail to destroy infection effectively. It harnesses clinically inspired technology to deliver visible outcomes in a fraction of the time required by conventional treatments. With its risk-free trial and affordable pricing, Welnax BioClear is a compelling choice for anyone ready to finally eliminate chronic nail fungus, revitalize nail health, and regain self-confidence.

    CLICK HERE TO BUY YOUR WELNAX BIOCLEAR FROM THE OFFICIAL WEBSITE AT MASSIVE DISCOUNT TODAY

    Media Contact:
    Contact Person: Francesca Potts
    Brand website: https://www.welnax.com/
    Email – francesca@welnax.com
    Company name: Welnax

    Disclaimer: This media platform provides the content of this article on an “as-is” basis, without any warranties or representations of any kind, express or implied. We do not assume any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information presented herein. Any concerns, complaints, or copyright issues related to this article should be directed to the content provider mentioned above.

    Photos accompanying this announcement are available at: 

    https://www.globenewswire.com/NewsRoom/AttachmentNg/241f5041-ddbe-4ba7-9f5e-bd7d1ab252e6

    https://www.globenewswire.com/NewsRoom/AttachmentNg/2987c0c5-3393-442e-87a6-d60eb9fd3592

    https://www.globenewswire.com/NewsRoom/AttachmentNg/c70ee478-0bd4-484a-aead-fecd9be758a8

    https://www.globenewswire.com/NewsRoom/AttachmentNg/6df77121-ce55-4bc2-8f36-f4c5b6fc0c4e

    https://www.globenewswire.com/NewsRoom/AttachmentNg/bbce87cc-0a4d-4bd5-9ed5-2fc0a1bcd824

    The MIL Network –

  • MIL-OSI Global: Can we really resurrect extinct animals, or are we just creating hi-tech lookalikes?

    Source: The Conversation – UK – By Timothy Hearn, Senior Lecturer in Bioinformatics, Anglia Ruskin University

    Artist’s rendering: Woolly mammoths once roamed large swathes of Siberia. Denis-S / Shutterstock

    From dire wolves to woolly mammoths, the idea of resurrecting extinct species has
    captured the public imagination. Colossal Biosciences, the Dallas-based biotech company leading the charge, has made headlines for ambitious efforts to bring back long-lost animals using cutting edge genetic engineering.

    It recently announced the birth of pups with key traits of dire wolves, an iconic predator last seen roaming North America more than 10,000 years ago. This followed on the heels of earlier project announcements focused on the woolly mammoth and the thylacine. This all fuels a sense that de-extinction is not only possible but imminent.

    But as the science advances, a deeper question lingers: how close must the result be to count as a true return? If we can only recover fragments of an extinct creature’s genome – and must build the rest with modern substitutes – is that really de-extinction, or are we simply creating lookalikes?

    To the public, de-extinction often evokes images of Jurassic Park-style resurrection: a recreation of a lost animal, reborn into the modern world. In scientific circles, however, the term encompasses a variety of techniques: selective breeding, cloning, and increasingly, synthetic biology through genome editing. Synthetic biology is a field that involves redesigning systems found in nature.

    One of Colossal’s dire wolves, created using genome editing.
    Colossal

    Scientists have used selective breeding of modern cattle in attempts to recreate an animal that resembles the auroch, the wild ancestor of today’s breeds. Cloning has been used to briefly bring back the pyrenean ibex, which went extinct in 2000. In 2003, a Spanish team brought a cloned calf to term, but the animal died a few minutes after birth.

    This is often cited as the first example of de-extinction. However, the only preserved tissue was from one female animal, meaning it could not have been used to bring back a viable population. Colossal’s work falls into the synthetic biology category.

    These approaches differ in method but share a common goal: to restore a species
    that has been lost. In most cases, what emerges is not an exact genetic copy of the extinct species, but a proxy: a modern organism engineered to resemble its ancestor in function or appearance.

    Take the case of the woolly mammoth. Colossal’s project aims to create a cold-adapted Asian elephant that can fulfil the mammoth’s former ecological role. But mammoths and Asian elephants diverged hundreds of thousands of years ago and differ by an estimated 1.5 million genetic variants. Editing all of these is, for now, impossible. Instead, scientists are targeting a few dozen genes linked to key traits like cold resistance, fat storage and hair growth.

    Compare that to humans and chimpanzees. Despite a genetic similarity of around 98.8%, the behavioural and physical differences between the two are huge. If comparatively small genetic gaps can produce such major differences, what can we expect when editing only a tiny fraction of the differences between two species? It’s a useful rule of thumb when assessing recent claims.

    As discussed in a previous article, Colossal’s dire wolf project involved just 20 genetic edits. These were introduced into the genome of a gray wolf to mimic key traits of the extinct dire wolf. The resulting animals may look the part, but with so few changes, they are genetically much closer to modern wolves than their prehistoric namesake.

    Colossal’s ambitions extend beyond mammoths and dire wolves. The company is
    also working to revive the thylacine (Tasmanian tiger), a carnivorous marsupial that was once native to mainland Australia, Tasmania and New Guinea. The last example died at Hobart Zoo in 1936. Colossal is using a genetic relative called the fat-tailed dunnart – a tiny marsupial – as the foundation. The goal is to engineer the dunnart’s genome to express traits found in thylacines. The team says it is developing an artificial uterus device to carry the engineered foetus.

    Colossal also has a project to revive the dodo, a flightless bird that roamed Mauritius until the 1600s. That project will use the Nicobar pigeon, one of the dodo’s closest living relatives, as a basis for genetic reconstruction.

    In each case, the company relies on a partial blueprint: incomplete ancient DNA, and then uses the powerful genome editing tool Crispr to edit specific differences into the genome of a closely related living species. The finished animals, if born, may resemble their extinct counterparts in outward appearance and some behaviour – but they will not be genetically identical. Rather, they will be hybrids, mosaics or functional stand-ins.

    That doesn’t negate the value of these projects. In fact, it might be time to update our expectations. If the goal is to restore ecological roles, not to perfectly recreate extinct genomes, then these animals may still serve important functions. But it also means we must be precise in our language. These are synthetic creations, not true returns.

    Technology to prevent extinction

    There are more grounded examples of near-de-extinction work – most notably the
    northern white rhinoceros. Only two females remain alive today, and both are
    infertile. Scientists are working to create viable embryos using preserved genetic
    material and surrogate mothers from closely related rhino species. This effort
    involves cloning and assisted reproduction, with the aim of restoring a population
    genetically identical to the original.

    Unlike the mammoth or the thylacine, the northern white rhino still has living
    representatives and preserved cells. That makes it a fundamentally different
    case – more conservation biology than synthetic biology. But it shows the potential of this technology when deployed toward preservation, not reconstruction.

    The northern white rhinoceros is nearly extinct. But there is a viable plan to bring it back.
    Agami Photo Agency / Shutterstock

    Gene editing also holds promise for helping endangered species by using it to introduce genetic diversity into a population, eliminate harmful mutations from species or enhance resilience to disease or climate change. In this sense, the tools of de-extinction may ultimately serve to prevent extinctions, rather than reverse them.

    So where does that leave us? Perhaps we need new terms: synthetic proxies, ecological analogues or engineered restorations. These phrases might lack the drama of “de-extinction” but they are closer to the scientific reality.

    After all, these animals are not coming back from the dead – they are being invented, piece by piece, from what the past left behind. In the end, it may not matter whether we call them mammoths or woolly elephants, dire wolves or designer dogs. What matters is how we use this power – whether to heal broken ecosystems, to preserve the genetic legacy of vanishing species or simply to prove that we can.

    But we should at least be honest: what we’re witnessing isn’t resurrection. It’s reimagination.

    Timothy Hearn does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    – ref. Can we really resurrect extinct animals, or are we just creating hi-tech lookalikes? – https://theconversation.com/can-we-really-resurrect-extinct-animals-or-are-we-just-creating-hi-tech-lookalikes-254245

    MIL OSI – Global Reports –

  • MIL-OSI Global: Sudan civil war: despite appearances this is not a failed state – yet

    Source: The Conversation – UK – By Justin Willis, Professor of History, Durham University

    Over the past fortnight, the Sudanese Armed Forces (SAF) have regained control of almost all of the country’s capital, Khartoum. Much of the city had been in the hands of the rival Rapid Support Forces (RSF) since April 2023. Now the SAF are reportedly driving out the last outposts of the RSF from the fringes of the sprawling city.

    When it began the war against its former SAF allies in April 2023, the RSF seized almost all of the city. But its presence was an occupation rather than a government. Looting, murder and rape were widely reported. No wonder, then, that many have welcomed the return of the SAF as a liberation.

    But not everyone will celebrate. The SAF claims to be the rightful government of Sudan. But its leader, Abdel Fattah Burhan, himself seized power in 2021 by throwing out a transitional civilian government that was supposed to be leading Sudan back to democracy.

    That was in the wake of the popular uprising in 2018-19 that ended the long authoritarian regime of Omar al-Bashir. So, the legitimacy of the SAF’s claim to power is questionable.

    To complicate matters further, the SAF’s military success has come through alliance with local militias, whose fighters have been active in the struggle for Khartoum. Troubling accounts have emerged of arrests and summary executions by the SAF and allied military – sometimes allegedly targeted at people from southern or western Sudan, who are accused of supporting the RSF.

    The RSF, meanwhile, keeps up its occupation of much of the west of Sudan, and its murderous siege of the western city of El Fasher. It has also continued to launch drone assaults on cities along the Nile.

    Despite recent positive statements from the SAF, the war seems far from over. The SAF and RSF denounce one another. Each – with good reason – accuses the other of relying on foreign support, and each insists it should – and will – rule all of Sudan.

    Military dominance

    The Egyptian branch of the Ottoman empire created Sudan through conquest in the 19th century. It was then ruled as an Anglo-Egyptian “condominium” for the first half of the 20th century.

    That vast territory in north-east Africa was formally divided when its southern third became the independent state of South Sudan in 2011, after years of struggle against the central government. Now it seems the north is also fragmenting, torn to pieces by the ambitions of rival military leaders and the unruly militias they have spawned. So, can there be a future for Sudan?

    It would be easy to answer that with a simple “no”. Some might even welcome the end of a state that began in colonial violence and has seen multiple regional revolts and movements of secession. Others might argue that Sudan is simply too diverse to be viable. But its current plight was not inevitable, nor is its fate settled.

    Sudan has long been burdened with a hyperactive military. That is partly a colonial legacy – the army has always been at the heart of the state.

    After independence, soldiers saw themselves as not simply the guardians of the state, but as its embodiment. They were at first suspicious – and then increasingly contemptuous – of civilian politicians they regarded as self-interested, prone to factionalism, and chronically unable to agree on major issues, from the place of religion in the state to the nature of local government.



    Read more:
    Sudan’s entire history has been dominated by soldiers and the violence and corruption they bring

    Three times, the soldiers seized power: in 1958, 1969 and 1989. Each time, they stayed in power for longer, and sought to impose their visions of what Sudan should be. Though these varied from conservative to socialist to Islamist, they always imagined a Sudan united by authoritarian rule, with uniformed men at its heart.

    When popular uprisings threatened this military rule, the soldiers were adept at temporary concessions – removing the leader of the regime and cooperating with civilians for a few years, before seizing power again. Sudan’s soldiers saw the state as their possession.

    Yet they struggled to rule it. There were struggles within the military itself over who should be in charge – the long rule of Jaafar Nimeiri was punctuated by repeated coup attempts. Omar al-Bashir in turn sought to manage rivals in the military by creating additional security forces and setting the soldiers against one another.

    When unrest grew at the margins of Sudan, in the south and then the west, the soldiers were unable to contain this. So they armed and encouraged militias, exploiting and militarising local tensions and conflicts. As they did so, they unwittingly undermined their own claim to be the only legitimate wielders of violence.

    Sudan’s soldiers insisted the state was theirs. But they squabbled over control of it and pulled both local militias and external powers into their struggles. This made their wars more lethal – but not more conclusive. Time and again, powerful men made decisions that drove conflict when they could have acted otherwise.

    Sense of a nation

    To recount this history is not simply to explain where Sudan is now. It is to remember this is not where it has to be. Sudan could yet mean more than this militarised vision of imposed unity. In the popular uprisings, protesters wrapped themselves in the Sudanese flag – evoking a vision of Sudan that celebrated its diversity, rather than treating this as a problem.

    Some of that was romanticised or idealistic. The earnest expressions of national solidarity tended to gloss over profound differences in wealth and opportunities. Yet since its independence, the idea of Sudan has repeatedly inspired civilian protest and hopes of a better future.

    The local resistance committees whose members made the uprising of 2018-19 imagined a more inclusive and just Sudan. That hope now drives the “emergency response rooms” that ordinary people have organised over the past two years – often in the face of extreme danger – to shelter and feed civilians.

    Those brave enough to pursue that future deserve more than a condescending shrug from international analysts, and an assumption that Sudan is doomed to failure.

    Justin Willis has in the past received funding from the UK government to undertake research on elections in Sudan; and from UK research councils for research on the history of state authority in Sudan.

    – ref. Sudan civil war: despite appearances this is not a failed state – yet – https://theconversation.com/sudan-civil-war-despite-appearances-this-is-not-a-failed-state-yet-254216

    MIL OSI – Global Reports –

  • MIL-OSI United Kingdom: UK and France convene first Defence Ministers’ Ukraine Coalition of the Willing meeting

    Source: United Kingdom – Executive Government & Departments

    Press release

    UK and France convene first Defence Ministers’ Ukraine Coalition of the Willing meeting

    UK and France convene defence ministers’ meeting in Brussels to progress planning to support a lasting peace in Ukraine

    Operational discussions to plan for a multinational reassurance force to support Ukraine in securing a lasting peace will progress today [April 10] with 30 defence ministers set to attend the latest Coalition of the Willing meeting.

    The Defence Secretary, John Healey, and his French counterpart, Minister Sébastien Lecornu, will host around 30 nations involved in planning for the Coalition of the Willing in Brussels later today.

    The meetings will focus on how the capabilities of each nation in the Coalition could be best used in supporting Ukraine’s long-term defence and security.

    The Prime Minister and Defence Secretary have both been clear that a lasting peace in Ukraine will require credible security assurances to deter Russian aggression. The UK has been stepping up to lead international support to keep Ukraine in the fight now and put them in the strongest possible position to secure peace.

    Addressing the meeting, Defence Secretary John Healey MP is expected to say:

    A couple of weeks ago, I visited the UK’s Permanent Joint Headquarters where military leaders from around 30 nations were developing options and progressing plans. I was struck by their sense of historic responsibility to secure the peace in Ukraine and to strengthen European security for all our nations.

    We cannot jeopardise the peace by forgetting about the war, so we must put even more pressure on Putin and step up our support for Ukraine – both in today’s fight and the push for peace. Our commitment is to put Ukraine in the strongest position to protect Ukraine’s sovereignty and deter future Russian aggression.

    The meeting today comes after the Chief of the Defence Staff Admiral Sir Tony Radakin, travelled to Kyiv with French military chiefs last weekend to meet President Zelenskyy, Defence Minister Umerov, and Ukrainian military leaders to update and discuss planning.

    Tomorrow, the Defence Secretary and German Defence Minister Boris Pistorius will chair the 27th meeting of the Ukraine Defence Contact Group, bringing together around 50 nations to drive forward additional military support for Ukraine in the face of ongoing Russian attacks.

    The UK convened and chaired the group in its latest format for the first time in February, with 46 nations in attendance, raising an extra 1.5 billion euros in military aid for Ukraine. These latest meetings come after the UK set the path to spending 2.5% of GDP on defence from 2027, and a boost to defence spending of £5 billion for this financial year, delivering on the government’s Plan for Change.

    This work delivers on the Prime Minister’s four-point plan to support Ukraine by ramping up delivery of weapons and equipment, boosting Ukraine’s defensive capabilities in the long term, working with allies to develop robust security assurances, and keeping up pressure on Putin.

    The UK is fully committed to working with allies to step up support to ensure Ukraine is in the strongest possible position to secure peace and is stepping up support – providing £4.5 billion of military support this year – more than ever before.

    This support is vital to European security but is also supporting growth across the UK, with defence as an engine for growth. Last month, the Prime Minister announced a historic £1.6 billion deal to provide more than five thousand air defence missiles for Ukraine – creating 200 new jobs and supporting a further 700. Defence supports more than 434,000 skilled jobs in the UK.

    The UK has sent around 400 different capabilities to Ukraine, with a £150 million package including drones, tanks and air defence systems announced on 12 February 2025, a £225 million package including drones, boats and munitions announced on 19 December 2024, and 650 lightweight multirole missiles announced on 6 September 2024.

    Updates to this page

    Published 10 April 2025

    Invasion of Ukraine

    MIL OSI United Kingdom –

  • MIL-OSI United Kingdom: Leicester school celebrates outstanding status

    Source: City of Leicester

    AN OUTSTANDING school in Leicester has been praised for maintaining standards in a recent Ofsted inspection.

    Catherine Infant School, in Belgrave, was inspected by Ofsted in February to see if it had taken effective action to maintain the standards identified at the previous inspection in 2019, when it was rated outstanding.

    The inspection found that the school has indeed maintained standards, despite a change of headteacher, deputy and chair of governors since the last inspection.

    Inspectors praised the school’s nurturing atmosphere and values of kindness, respect, resilience and a love of learning, which they said ‘sit at the heart of all that it does’.

    They said that pupils – who range in age from 3 to 7 – thrive and are very happy at the school. There is a ‘rigorous and ambitious’ curriculum and the school places a high priority on pupils learning to read – and as a result they make ‘an excellent start’ in early years education.

    Pupils’ behaviour was described as ‘exemplary’, and the school was also praised for quickly identifying and supporting pupils who need extra help, as well as pupils with special educational needs (SEN) and disabilities. The school has a SEN unit funded and supported by the city council, as part of the council’s Designated Specialist Provision (DSP) across the city. 

    The school has also relocated to a new building since the last inspection, as part of a Government rebuilding scheme for ageing schools, with an official opening event planned for the summer term.

    Headteacher Mitesh Madhaw said: “We are absolutely delighted with the outcome of our recent Ofsted inspection, which recognises the dedication, passion, and hard work of our entire school community.

    “Being rated ‘outstanding’ is a tremendous achievement and a reflection of the relentless commitment of our staff, the enthusiasm of our pupils, and the unwavering support of our parents and governors. We are proud to provide a nurturing and ambitious environment where every child can thrive. This report affirms that our shared vision and values are not only being lived every day, but are making a real and lasting impact. We will continue to strive for excellence and ensure our school remains a place where children love to learn and grow.”

    Cllr Elaine Pantling, assistant city mayor for education, said: “This is absolutely excellent news for Catherine Infant School, which – like all our schools – the local authority is very proud to support.

    “The glowing praise in this inspection shows what a wonderful impact parents, teachers, governors and the local community can have on children when everyone works together to create a caring and inspirational learning environment.

    “I congratulate the whole school community on this outcome, and very much look forward to visiting them next term to see their new building!”

    The Ofsted report can be viewed at https://files.ofsted.gov.uk/v1/file/50273123

    ENDS

    MIL OSI United Kingdom –

  • MIL-OSI NGOs: MSF steps up response in Myanmar following devastating earthquake

    Source: Médecins Sans Frontières –

    On 28 March 2025, a powerful 7.7 magnitude earthquake struck central Myanmar, devastating the regions of Mandalay, Naypyidaw, Sagaing, and Shan state. As of 8 April, official figures reported over 3,600 deaths, more than 5,000 people injured, and an estimated 17 million individuals affected — many of whom are severely affected. Key infrastructure, including hospitals, roads, and water systems, sustained significant damage, while ongoing telecommunications disruptions continue to hamper relief efforts.

    The earthquake struck a country already gripped by several health crises and ongoing conflict, compounding the challenges faced by affected communities. Limited resources, including staff and supplies, have left some facilities over-burdened and struggling to respond to people’s growing health needs.

    In the immediate aftermath, Médecins Sans Frontières (MSF) reaffirmed our commitment and capacity to deliver large-scale emergency medical assistance across all impacted areas. We have prioritised our response in the hardest-hit and currently accessible cities of Mandalay and Naypyidaw, while serious concerns persist for people living in more remote and less accessible areas, such as Sagaing.

    View of the destruction caused by the earthquake in Kumae township. Myanmar, March 2025.
    MSF

    Our staff have reported extensive destruction. Many residents remain outdoors, fearing aftershocks, while monasteries have opened their doors to host displaced families and local communities are demonstrating remarkable solidarity.

    Healthcare  

    In the hardest-hit cities, damage to infrastructure has disrupted essential services like water, electricity, and sanitation, severely impacting hospitals’ ability to function. In some cases, structural damage forced medical staff to treat patients outside, due to fears of further building collapse.  

    In Naypyidaw and Mandalay, where hospital systems were particularly hard hit, MSF carried out assessments, delivered medical supplies, and initiated discussions with key stakeholders, including the Ministry of Health.  

    A volunteer providing psychological first aid to a patient admitted after the earthquake in Mandalay Teaching hospital. Myanmar, April 2025.
    MSF

    Water and sanitation, shelter, and basic items  

    In Mandalay, MSF teams quickly moved to improve water, sanitation, and hygiene conditions in damaged hospitals by installing water tanks and additional handwashing basins. Waste management was reinforced with dozens of bins, and fans were set up in temporary shelters to help patients cope with extreme heat – often reaching 40°C – while awaiting treatment outside damaged facilities.

    At the same time, mobile medical teams began providing consultations in makeshift shelters, including monasteries, treating a range of conditions from common illnesses to chronic diseases such as diabetes and hypertension. In southern Shan, mobile teams also distributed essential items, restored clean water sources, and continued assessments in affected and displaced communities. 

    An MSF team delivers water tanks to Mandalay hospital, Myanmar, April 2025.
    MSF

    Psychological impact of the earthquake 

    Mental health is a key part of MSF’s response. In Mandalay, teams composed of trained staff and student volunteers have been visiting patients in surgical, orthopaedic, and trauma wards at local hospitals to provide psychological first aid. These efforts are essential in a context where survivors face high psychological stress following both the disaster and fear of aftershocks, which continue to be recorded, and in addition to the consequences of the ongoing conflict ravaging many parts of the country. 

    Major concerns about expected environmental impacts to come 

    With the rainy season approaching, flooding and landslides could exacerbate existing access challenges, particularly in remote areas. The rainy season also significantly heightens the likelihood of public health threats associated with outbreaks of waterborne disease such as cholera, and vector-borne diseases like malaria or dengue fever. This is due to the potential flooding-related contamination of the already reduced number of safe water sources. Immediate actions like scaled up provision of clean water, safe sanitation facilities, distribution of mosquito nets and hygiene promotion are essential to mitigate the additional threads.  

    Volunteers provide psychological first aid to people through mobile clinics in a temporary camp in Chan Mya Thar Si township, Mandalay, Myanmar, April 2025.
    MSF

    What needs to happen now? 

    In order to address the immense needs, it is crucial for humanitarian aid to reach all affected areas unhindered, including hard to reach locations. A further significant scale-up of aid and access to healthcare in all affected areas, is urgently needed to avoid longer-term harmful consequences for people grappling with the aftermath of this earthquake.

    As part of our long-standing presence in Myanmar since its first intervention in 1992, MSF reaffirms our readiness to provide emergency medical humanitarian assistance wherever needed, as we continue to support communities affected by conflict, disease, and now, one of the worst earthquakes to strike the region in recent history.  

    MIL OSI NGO –

  • MIL-OSI NGOs: Peter Dutton must reject Trump-style plan to leave Paris Agreement

    Source: Greenpeace Statement –

    SYDNEY, Thursday 10 April 2025 — In response to comments by Shadow Energy Minister Ted O’Brien that the Coalition could leave the Paris Agreement if elected, David Ritter, CEO at Greenpeace Australia Pacific, said:

    “Abandoning the Paris Agreement is a terrible idea, straight out of Donald Trump’s playbook, that would harm our economy, our global standing, and our relationship with our Pacific neighbours. 

    “Australia is the world’s third-largest fossil fuel exporter, and a major polluter with an outsized responsibility to cut our emissions at emergency speed and scale. As the cost of back-to-back climate disasters grows, we are also paying a heavy price for climate change. 

    “Shrinking our climate targets and walking away from international cooperation on reducing emissions and climate finance will harm our economy as the world moves to decarbonise and alienate our Pacific neighbours on the frontlines of climate change. It would not be in our national interest to leave the Paris Agreement. 

    “It is shocking that the Coalition is even entertaining the possibility of abandoning this important global climate accord, which is our best chance at averting catastrophic climate change. Peter Dutton should distance his party from this Trumpian tactic and commit to keeping Australia in the Paris Agreement in no uncertain terms.”  

    — ENDS —

    For more information or interviews contact Vai Shah on 0452 290 082 or [email protected] 0452 290 082

    MIL OSI NGO –

  • MIL-OSI NGOs: ‘Ambitious but sensible’: Greenpeace welcomes Greens’ plan for clean jobs and climate solutions

    Source: Greenpeace Statement –

    SYDNEY, Thursday 10 April 2025 — In response to the release of The Greens’ Powering Past Coal and Gas energy plan released today, Joe Rafalowicz, Head of Climate and Energy at Greenpeace Australia Pacific, said:

    “Greenpeace welcomes The Greens’ Powering Past Coal and Gas plan released today. Not only does the plan respond to the scale and urgency of the climate crisis we all face, it centres communities on the frontlines of climate impacts, and everyday Australians struggling with cost of living pressures, rising power bills and soaring insurance premiums.

    “It is an ambitious but sensible plan that prioritises investment in the solutions we already have to tackle climate pollution — things like public transport, clean and affordable wind and solar energy, protecting our forests and nature — while also outlining a clear pathway for sustainable jobs and economic growth as we transition our economy from fossil fuels.

    “Multinational gas corporations like Woodside and Santos are holding Australia’s economy hostage for their own profit by blocking our transition to a clean energy economy — and they’re destroying the nature and oceans we love in the process. This plan sends a strong signal that Australia’s future is in green jobs, healthy oceans and climate solutions, not dirty coal and gas shipped offshore.

    “With our skilled workforce, export infrastructure, and unparalleled access to wind and solar energy, Australia can be front of the pack in exporting the resources our trading partners need to rapidly decarbonise their economies — and in doing so, support global efforts to address carbon emissions.

    “The climate crisis is here and it’s hurting Australians and our economy now — this year alone we’ve seen record-breaking floods, and a freak cyclone, devastate communities across the country. Instead of flying in for photo opps in the aftermath, we urge all candidates this election to fight for the policies that will stop climate pollution before it happens.”

    — ENDS —


    For more information or interviews contact Kate O’Callaghan on 0406 231 892 or [email protected]

    MIL OSI NGO –

  • MIL-OSI Banking: Axsome Therapeutics’ AXS-05 challenges current standard of care as promising non-antipsychotic for Alzheimer’s agitation, says GlobalData

    Source: GlobalData

    Axsome Therapeutics’ AXS-05 challenges current standard of care as promising non-antipsychotic for Alzheimer’s agitation, says GlobalData

    Posted in Pharma

    Download M&A Report Click to view Global M&A Review and League Tables

    At the recently held American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation associated with Alzheimer’s disease (AD). With a novel, non-antipsychotic mechanism and a favorable safety profile, AXS-05 addresses a critical unmet need in managing distressing behavioral symptoms, potentially reshaping the current treatment paradigms in a space largely reliant on off-label antipsychotic use, says GlobalData, leading data and analytics company.

    Pippa Salter, Managing Neurology Analyst at GlobalData, comments: “A major unmet need in the AD market is for treatments for the many secondary symptoms associated with the disease that can negatively impact the quality of life for both patient and caregiver, with agitation highlighted by the key opinion leaders (KOLs) previously interviewed by GlobalData as a particularly distressing symptom with a lack of good treatment options.”

    When agitated, patients are often prescribed antipsychotic medications and sedatives off-label to alleviate behavioral issues, a practice that the FDA states can be dangerous in elderly patients. In 2023, Otsuka Pharmaceuticals’ atypical antipsychotic Rexulti (brexpiprazole) became the first FDA-approved treatment for agitation associated with AD in the US.

    Salter continues: “KOLs felt that the efficacy of Rexulti was only comparable to other atypical antipsychotics and thus not providing a significant breakthrough for AD agitation treatment. The positive efficacy for AXS-05 is particularly significant therefore as if approved it would provide a novel, non-antipsychotic treatment option for AD agitation. Additionally, in the ACCORD-2 trial AXS-05 was well tolerated, and its benign safety profile, combined with physician experience with the drug for treating major depressive disorder should give AXS-05 a further competitive advantage in the AD market.”

    GlobalData’s report “Alzheimer’s Disease in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033,” reveals that AXS-05 will generate US sales of approximately $307.3 million in the AD market in 2033.

    Salter concludes: “Other products in late-stage development for AD agitation with novel mechanisms of action, including Suven Life Sciences’s 5-hydroxytryptamine receptor 6 antagonist masupirdine and BioXcel Therapeutics’ alpha 2 adrenergic receptor agonist Igalmi (dexmedetomidine), will provide competition for AXS-05. And with Axsome Therapeutics and BioXcel Therapeutics currently focusing on development in the US only, significant opportunity for targeting AD agitation will remain outside of the US.”

    MIL OSI Global Banks –

  • MIL-OSI Banking: APAC automakers face uncertainty as US tariffs trigger strategic recalibration, finds GlobalData

    Source: GlobalData

    APAC automakers face uncertainty as US tariffs trigger strategic recalibration, finds GlobalData

    Posted in Automotive

    The 25% US tariff on foreign automobiles and parts has created deep uncertainty for Asia-Pacific (APAC) automakers. With significant exposure to the US market, they now face rising costs, strained supply chains, and pressure to shift production. The temporary 90-day hold on the updated tariff, announced on 09 April 2025, offers a brief respite while negotiations with trade partner countries continue. As negotiations continue, the APAC automakers brace for long-term changes to global trade and manufacturing strategies, observes GlobalData, a leading data and analytics company.

    Hyundai’s exports to the US account for 16% of its total export volume, while Subaru’s exports represent 32%, and Toyota’s exports make up 5%. This substantial exposure to the US market means that these manufacturers are particularly vulnerable to the repercussions of the tariff increase.

    Madhuchhanda Palit, Automotive Analyst at GlobalData, comments: “While major automakers like Toyota Motor have reported record profits, small and medium-sized suppliers are expressing concerns. Rising raw material and labor costs have made it increasingly challenging for these firms to pass expenses onto clients, particularly in light of wage increases.

    “The impending tariffs could exacerbate these challenges, as larger manufacturers may consider relocating production to the US, potentially jeopardizing the livelihoods of local suppliers. The automotive ecosystem, particularly in countries such as Japan, is at risk, with small businesses reliant on larger automakers facing heightened instability.”

    In response, Subaru has already alerted its dealers that current pricing cannot be guaranteed and may be subject to change. Conversely, Hyundai has launched a Customer Assurance program to alleviate consumer concerns about the uncertainty. Meanwhile, Toyota, which already has a significant production presence in the US, has announced no intention to raise vehicle prices and is focusing on reducing fixed costs.

    In a strategic move, Nissan, initially reconsidering its EV production timeline in the US prior to the tariff announcement, has now confirmed plans to relocate part of its production to the US. This mirrors a broader trend, with Hyundai committing $21 billion, including a $5.8 billion steel plant in Louisiana, and Toyota investing $14 billion in its first in-house battery plant outside Japan, located in North Carolina.

    Palit  explains: “While the US automotive market and manufacturers may face turbulence in the short-run due to the tariffs, increased investments in domestic production are likely to strengthen the US economy over time and could prove beneficial for both manufacturers and consumers alike.”

    As manufacturers explore various strategies to navigate this turbulent landscape—including potential production shifts and price guarantees for consumers—the broader consequences for the automotive sector and its ecosystem remain to be seen.

    Palit concludes: “The temporary hold on the tariffs provides a crucial window for negotiations that could ease the current situation. However, the ongoing discussions and evolving trade dynamics will play a critical role in determining the future stability and profitability of the APAC automotive industry. As the industry adapts to these changes, the focus will remain on innovation and maintaining a competitive stance in the global automotive market.”

    MIL OSI Global Banks –